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Development of Methods for the Discovery of Small Molecule Biological Probes 	
Carrie Elizabeth Yozwiak 	
Advances in combinatorial chemistry have facilitated the production of large 
chemical libraries that can be used as tools to discover biological probes and therapeutics.  
High-throughput screening (HTS) strategies have emerged as the standard method to 
assess the biological activity of small molecules. These screens involve the individual 
analysis of each small molecule in multi-well plates, often requiring expensive automated 
methods and development of robust assays that may not translate to physiologically 
relevant contexts.   
This problem of evaluating large numbers of reagents in physiologically relevant 
cell and animal models has been addressed for genetic reagents such as RNAi, CRISPR, 
and cDNA by creating barcoded retroviral libraries that can be used to infect target cells 
in culture or in animal models. Using these tools, effective reagents can be selected and 
decoded using a rapid and inexpensive procedure compared to testing of individual 
reagents one at a time in an arrayed fashion. In order to more efficiently analyze small 
molecules, a pooled approach would similarly be useful. 
This dissertation describes the studies towards developing a pooled screening 
strategy for small molecules in cellular contexts. Through an initial screen, we set to 
phenotypically profile small molecule biological activity in a pooled fashion, while 
simultaneously gain insight about an individual, active molecule’s mechanism of action. I 
first describe the design of the pooled screen and define the goals necessary for 
successful application. Next, I outline the steps taken and challenges encountered during 
the invention of each component of the technology. Finally, I discuss a computational, 
target-based approach to design small molecules appropriate for future applications of the 
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1.1 Screening Methods in Drug Discovery 
The process to develop a new small molecule therapeutic from conceptualization to 
the clinic is extremely resource intensive and arduous (Hughes et al., 2011). Additionally, 
advances in combinatorial chemistry have facilitated the production of large numbers of 
novel chemical compounds to be tested for biological activity (Lee et al., 2012; Li et al., 
2013). To efficiently assess the therapeutic potential of each of these drug-like small 
molecules, high-throughput screening (HTS) strategies have emerged as the industry and 
academia-wide standard method to accelerate drug discovery. These assays take 
advantage of automated screening methods to gain information about the activity of large 
libraries of chemical compounds for the disease of interest. The implementation of high-
density multi-well plates for arrayed HTS assays makes it possible to test thousands of 
small molecules for biological activity per day (Szymanski et al., 2012). 
High-throughput screens can be designed following two distinct philosophies: target-
based drug design and phenotypic screening.  
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1.2  Target-based Drug Discovery 
Target-based drug discovery is a hypothesis-driven approach that attempts to 
discover small molecules that very specifically modulate a particular gene, protein, or 
other defined biological ‘target’ with the goal of affecting the disease state by probing a 
distinct, understood pathway implemented in pathogenesis (Swinney, 2013). This rational 
and systematic approach to discovering small molecules that possess a defined 
mechanism of action was made possible through advances in genetics and molecular 
biology that allows for elucidation of particular protein targets and a more thorough 
picture of biological pathway components (Schenone et al., 2013).  
Target-based discovery tactics rely on clearly understanding the biological basis 
of disease, allowing the scientist an opportunity to select a relevant biomarker to quantify 
the severity of the physiological disease state and predict which patient populations may 
respond to the particular drug (Dessi et al., 2013). A biomarker can be defined as a 
measurable biological indicator of (1) disease or (2) response to therapeutic intervention, 
and provides an objective means by which to quantify health state and determine 
therapeutic efficacy (Strimbu and Tavel, 2010). By understanding both the drug 
mechanism of action and the role the therapy assumes in the pathophysiology of the 
disease, co-development of a drug and a companion diagnostic for therapeutic efficacy is 
possible (Garcia et al., 2011). This strategy enables the selection of a suitable patient 
population for biomarker-driven clinical trials, thereby shortening the timeline needed to 
bring a drug to market (Dienstmann et al., 2013). Biomarker-driven clinical trials have 
been shown to be efficacious in oncology, where patient populations are selected based 
on molecular features of their tumors (Tan et al., 2009). This approach has been 
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successfully implemented in the development of the PARP (poly(ADP-ribose) 
polymerase) inhibitor olaparib for ovarian and breast cancer treatment. Clinical trial 
populations were enriched for carriers of BRCA1 or BRCA2 mutations, which are the 
genetic aberrations that served as biomarkers indicative of therapy efficacy (Fong et al., 
2009). 
 Once a protein target essential to disease biology is elucidated and a hypothesis 
of how it is implicated in disease is put forth, there are a variety of methods by which to 
embark on the search for a small molecule therapeutic candidate that preferentially 
engages with this target. The most commonly employed approaches of screening for 
small molecule lead compounds include 1) computer-aided drug design, 2) fragment-
based screening and 3) high-throughput screening of lead-like compounds. 
 
1.3 Computer-Aided Drug Design 
Computer-aided drug design (CADD) involves the computational modeling of 
drug-receptor interactions to simulate the affinity for which a given small molecule has 
for its target protein (Sliwoski et al., 2014). In drug discovery efforts, computer-aided 
approaches can be used to predict which small molecules are the most promising 
candidates for experimental validation, thus reducing the time and cost associated with 
experimentally screening large libraries chemical compounds. Additionally, CADD also 
provides valuable insight into the specific pose a small molecule assumes when 
interacting with a receptor, which greatly assists the scientist in rationally elaborating 
upon and optimizing the structure of the lead small molecule to enhance pharmaceutical 
properties while maintaining target affinity (Baig et al., 2016).  
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Historically, successful applications of CADD have been achieved as early as the 
1990s with the development of HIV protease inhibitors (Liao and Nicklaus, 2010), and 
continued to play an essential role to efficiently identify drug hits and leads (Becker et 
al., 2006; Boehm et al., 2000; Doman et al., 2002; Santos et al., 2015). The first HIV 
protease inhibitor, ritonavir, was discovered using structure-based approaches and was 
approved by the FDA in only 72 days. This drug required only eight years for 
development (Sliwoski et al., 2014), which is about half of the conventional timeline for 
a therapeutic to come to market. The efficient process was attributed to the successful 
implementation of CADD. 
CADD can further be broken down into two broad categories of in silico 
techniques: 1) ligand-based drug design and 2) structure-based drug design. Structure-
based methods are employed when there is an available three-dimensional structure of the 
target protein, whereas ligand-based methods are used when the protein structure of 
interest is unavailable (Baig et al., 2016). 
 
1.4 Ligand-based drug design 
If the structure of the protein target is unknown, but there are small molecules that 
have been identified to exhibit biological activity against the target of interest, indirect 
computational methods can be employed to find a better therapeutic candidate. In this 
ligand-centric approach, the structure of a small molecule can be broken down so that the 
characteristics of each atom in the molecule are recognized to represent a physical 
interaction (hydrogen bond donor, hydrogen bond acceptor, hydrophobicity, pi-
interaction, etc.) with the protein that may be responsible for its observed biological 
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activity (Yang, 2010). Once the structure of the molecule is analyzed using the three-
dimensional orientation of its steric and electronic features, a pharmacophore model is 
created and then superimposed with low-energy conformations of other small molecules. 
(Kapetanovic, 2008). In theory, if one physical phenomenon, like hydrogen bonding, is 
preserved in a similar region of superimposed chemical compounds, the interactions of 
small molecules with similar pharmacophores in the binding pocket of the biological 
target should remain. This strategy is especially useful when optimizing a lead compound 
for ADME properties or assessing whether drugs can have multiple biological targets 
(Lee et al., 2011).  
 
1.5 Structure-based drug design 
Structure-based drug design is a direct approach wherein small molecules are 
computationally fit into a three-dimensional protein structure. This protein structure can 
be elucidated by x-ray crystallography or NMR spectroscopy with good resolution 
(usually less than 2.5 angstroms), or virtually created using homology modeling of 
similar proteins of known structure (Anderson, 2003). With this structural data in hand, 
scientists can use the topography of the biological receptor to visualize the 
stereochemical and electronic interactions of small molecules with the target protein and 
tune the small molecule structure to optimize receptor binding affinity.  
To virtually examine the binding affinity of a small molecule ligand for its target 
protein, molecular docking strategies are used. This technique most commonly involves 
the sampling of all possible three-dimensional orientations of a ligand into a fixed 
binding pocket on the receptor. Each of these docking poses is then ranked based on 
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binding affinity for the designated receptor (Gane and Dean, 2000). Molecular docking 
approaches are commonly applied in three ways that differ based on their computational 
complexity, and include (1) rigid docking (the least computationally complex), in which 
both the ligand and receptor geometries are held static in space, (2) flexible ligand 
docking, in which the conformation of the ligands is considered flexible, while the 
receptor is held rigid, and (3) the most complex simulation, flexible docking, in which 
both the ligands and target receptor geometries are considered flexible in space (Liao et 
al., 2011).  
Once a docking strategy is selected, structure-based virtual screening can occur. 
This approach involves docking large, in silico libraries of small molecules into the target 
receptor to assess binding affinity. After docking each individual ligand, the most 
probable binding mode for each small molecule is predicted, and the quality of fit of this 
optimal binding mode for the designated target site is scored to predict binding affinity. 
This computational approach can be considered the virtual equivalent of high-throughput 
screening and is used to efficiently identify lead compounds to be synthesized and 
biologically evaluated (Lionta et al., 2014). 
The ranking of goodness of fit for the ligand to the receptor, known as the 
docking score, of each ligand is taken into account to determine the subset of small 
molecules to further pursue and validate experimentally. The docking score is used to 
quickly and accurately evaluate the protein-ligand complex to differentiate accurate 
binding predictions from inaccurate modes. The aim is to achieve a good picture of which 
molecule will perform best empirically (Ferreira et al., 2015).  
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Scoring functions can be broken down into different categories based on what 
parameters each take into account. Force-field or molecular mechanics-based scoring 
functions use the sum of the electrostatic and van der Waals interactions to estimate the 
binding free energy of protein-ligand complexes. The physical atomic parameters 
included in this scoring function are derived from both ab initio quantum mechanical 
calculations and experimental data (Huang et al., 2010). Methods to account for the 
solvent effect on ligand binding present a major challenge to this method of scoring. To 
address this limitation, empirical scoring functions are commonly taken into 
consideration with force field functions.  
Empirical scoring functions use weighted energy terms, like hydrophobicity, 
desolvation, electrostatics, entropy, etc. to approximate the binding affinity of the ligand 
for the target. The simple model of counting the number of favorable and unfavorable 
interactions between the small molecule and protein make this method most efficient in 
scoring assessment (Kitchen et al., 2004).  
Knowledge-based scoring functions take into account experimentally determined 
parameters from known structure analysis. The interaction to be assessed is broken down 
atomistically, and the overall docking score is a sum of each individual atom-atom 
interaction. Because this approach relies on data collected from protein structural 
databases, molecular interactions that are not commonly accounted for in crystal 
structures, like cation-pi interactions or halogen bonding, are inadequately predicted. 
Consensus scoring functions take combinations of empirical, force-field, and knowledge 
based scoring functions in attempt to moderate the weaknesses of each individual method 
(Kitchen et al., 2004). 
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1.6 Fragment-based screening 
 Fragment-based screening involves the experimental analysis of low molecular 
weight (<300 Da) small molecules with the defined target protein by mass spectrometry, 
nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, or in vitro 
biophysical assays (Rees et al., 2004). Although small fragment libraries have less 
functionality and therefore react more weakly with their target protein (a hit would be 
considered low mM to 30 µM range), the power in this method originates from the 
understanding that drug-like molecules can be dissected and simplified to contain a 
combination of distinct binding epitopes (or fragments). Screening for these binding 
epitopes, and then amalgamating the most promising fragments to build a larger, more 
potent active molecule, forms the essence of this tactic (Hajduk and Greer, 2007). 
 Compared to high-throughput screening approaches, fragment-based screening 
offers distinct advantages. Fragment-based screens can often comprise smaller libraries 
of chemical compounds than the libraries of larger, drug-like small molecules because 
smaller molecules more efficiently sample chemical space than larger molecular weight 
compounds (Hall et al., 2014). This leads to an efficient increase in information gained 
by the scientist over an initial screen; a larger representative set of chemical moieties is 
sampled to initially provide empirical data supporting which epitopes show affinity, 
leading to the discovery of molecular templates that conventional HTS may have 
overlooked. Additionally, the chemical simplicity of fragments allows the researcher to 
understand which moieties are reactive to a specific binding site while also demonstrating 
a higher hit rate since a smaller molecule exhibits less steric hindrance for the binding 
site, although at weaker affinity (Mortenson et al., 2014). 
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The binding information gained from fragment-based screens can also be 
extremely valuable when deciding on how to elaborate upon the fragment to better create 
the drug-like molecule--smaller fragments provide more freedom by which the medicinal 
chemist can embellish the structure to optimize affinity, selectivity for the target, and 
ADME properties for drug-success. A low-molecular weight, simple compound starting 
point expands the potential avenues a medicinal chemist can explore, generating a larger 
amount of novel chemical structures for diversity (Doak et al., 2016). 
 
1.7 Challenges in target-based drug design 
 Conceptually, target-based drug discovery is a reductionist approach to 
therapeutic invention. The drug-organism interaction analysis is simplified to the study of 
the relationship of the drug for an individual target, which allows scientists to rationally 
design small molecules that address their hypothesized biological drivers of disease 
(Sams-Dodd, 2005). Although this route has triggered immense scientific advances into 
the understanding of disease progression and human biology, there are disadvantages to 
this tactic of drug discovery.  
Validation of the target’s role in human disease is critical to the drug development 
success, as even if a small molecule demonstrates potent and selective affinity for the 
defined protein, activation or inhibition of the target pathway may show no beneficial 
augmentation of disease state (Brown, 2007). One of the most powerful methods to 
demonstrate that a protein is instrumental in disease pathogenesis is to examine its 
implications in animal models of human disease, but often, development of an 
appropriate animal model is extremely challenging. Other methods of validation, 
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including proteomics, genomics, or computational modeling are efficacious to determine 
the functional role of a target protein in vitro, but each does not address the physiological 
complexity presented by a whole organism and does not present a comprehensive picture 
of whether the target is an essential driver of disease (Smith, 2003). 
Approaching drug discovery from a target-based standpoint requires the 
detachment of physiology from drug design. Medicinal chemists prioritize the fit of the 
small molecule for the receptor, and adjusting the small molecule structure to optimize 
ADME properties are accounted for secondarily. Even if the small molecule demonstrates 
activity in vitro, it may be unable to access the appropriate location to functionally act, 
whether this involves low cell permeability or ineffective blood brain barrier penetration. 
Additionally, the molecule may fail plasma or metabolic stability testing, rendering the 
candidate futile for human consumption. Because small molecules are initially screened 
for their ability to probe a specific mechanistic pathway, the rate of ‘hit’ small molecules 
is inherently lower than in systematic phenotypic screens, while the physiological 
consequences of altering a well- defined portion of a whole organism’s biology are not 
initially considered. Often, therapeutic candidates are not tested in animal models of 
disease until late in the production timeline, and molecules that have been thoroughly 
studied in silico and in vitro may be ineffective because the binding of the drug to the 
target may not sufficiently cause the relevant activity, or the engagement of a single 
target may not overcome the complexities of the disease state to elicit the desired 
physiological effect. Candidates may also be deemed unsafe because they cause off-target 
effects, and then rendered unfit to progress into the clinic.  
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1.8 Phenotypic Screening 
Phenotypic screening is a systems-based, unbiased screening approach that 
involves testing a large number of small molecules in a biological system and observing 
how the compound alters the physiological state of the complex, disease-relevant model 
(Zheng et al., 2013). This approach does not require the elucidation of a defined 
biological target. Instead, lead compound determination relies on whether the molecule 
produces the desired biological effect, thus ensuring that the biology and chemistry are in 
sync from the initial stages of the discovery process (Mullard, 2015). 
Phenotypic screens are essential to develop therapies for diseases in which 
specific biological targets have not been validated. In these cases, large numbers of 
randomly selected small molecules are screened for biological activity in functional 
assays. The major advantage of this method is that the ‘hit’ small molecules selected 
from these assays are more likely to possess therapeutically relevant molecular 
mechanisms of action, even if the specific way in which they function is unexpected or 
undetermined (Swinney, 2013). For example, the antibiotic linezolid was discovered 
through a phenotypic screen with live bacteria. This drug exhibits activity against multi-
drug resistant gram-positive pathogens, and laid the foundation for elucidation of 
oxazolidinones, an entirely new class of antibiotics (Swaney et al., 1998; Wilson et al., 
2008). 
Phenotypic assays have been used to both elucidate clinically relevant therapies 
and provide great insight into the biological mechanisms of disease, which can lay the 
groundwork for target-based discovery approaches. When the disease biology is 
unknown, careful consideration should be made to select an assay system that is most 
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physiologically representative of the disease under examination (i.e., through the use of 
primary or patient derived cells instead of immortalized human cancer cell lines) 
(Vincent et al., 2015). Indeed, phenotypic assays have successfully demonstrated 
translational value. Patient-derived airway epithelial cells were used as an excellent in 
vitro model of cystic fibrosis, and a phenotypic screen led to the discovery of the first 
therapies that improve lung function in patients who possess G551D and F508del 
mutations (Ashlock and Olson, 2011). 
Despite examples of successes, phenotypic screens have limitations towards drug 
discovery. Often, it is difficult to create assays that appropriately portray biological 
conditions of disease. When applied to oncology, cell based assays are often designed 
using immortalized human cancer cell lines, which are widely considered to be a poor 
representation of malignancy. Furthermore, assays developed to screen for cytotoxic 
agents by investigating cell viability often reveal drug-like candidates that bind to 
established and extensively drugged targets; small molecules screened hit the ‘low 
hanging fruit’ of proteins and rarely expand upon the disease mechanism of action, 
making discovery of novel classes of drugs challenging through this method. Because 
phenotypic screens do not elucidate the biological target upon which the candidate 
compound acts, it is often difficult to discover a biomarker to assess future phase trial 
efficacy en route to market. The hunt for the mechanism of action of hits derived from 
phenotypic screens can often lead researchers on a time-intensive ‘wild goose chase’ that 
may not deliver answers. 
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1.9 Combinatorial library synthesis 
Efficient screening strategies are dependent on the accessibility of large small 
molecule libraries. Merrifield’s revolutionary development of solid –phase peptide 
synthesis set the stage for technologies that generate large libraries of diverse peptides 
and small molecules (Merrifield, 1963). Split-pool synthesis methods rely on chemical 
conjugation of peptides or small molecules to a resin in a one-bead-one-compound 
(OBOC) format. After the initial coupling reaction is performed on different aliquots of 
beads, the beads are pooled and re-split, and a new moiety is added to each group of 
beads. This cycle of split-pool synthesis is repeated to efficiently generate large libraries 
of structurally diverse compounds for screening (Furka et al., 1991; Lam et al., 1991; Tan 
et al., 1998).  
Once the small molecules are cleaved from the beads after the completion of 
library synthesis, phenotypic, arrayed screens using the small molecule libraries have 
shown success in the discovery of biologically relevant compounds with novel properties 
(Lokey, 2003). Using biomimetic reactions on beads to generate a small molecule library 
of 2,527 compounds, Pelish et.al. discovered a structurally unique galanthamine-like 
small molecule that perturbs the secretory pathway in mammalian cells; a pathway 
distinct from the acetylcholinesterase inhibitory biological activity of the native 
galanthamine natural product (Pelish et al., 2001). In order to identify the small molecule 
that exhibits biological activity from this diversity oriented approach, each molecule in 
the library must be tested individually in multi-well plates to avoid complex 
deconvolution. 
Screening of these compound-bead libraries has been demonstrated in isolated 
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protein systems, but not in intact cells without release of the small molecule from the 
bead, because cells generally do not internalize the synthesis beads used for split-pool 
synthesis (Chen et al., 1993; You et al., 1997).  
Additionally, evaluating the effects of compounds in vivo in animal models 
requires great time, expense and numbers of animals, since these compounds must be 
tested in a one molecule per one animal basis.  
 
1.10 Pooled approaches to screening 
To improve the efficiency of testing large libraries of reagents for biological 
activity, pooling methods provide an alternative to arrayed high-throughput screening 
strategies. In a pooled screen, mixes, or ‘pools’ of candidate compounds or RNA are 
tested simultaneously in one well, as opposed to individually testing each component of 
the collection (Kainkaryam and Woolf, 2009).  
Pooling has emerged as a powerful approach to efficiently perform genetic 
screens. Specifically, pooled RNAi barcode screens provide a convenient method to 
evaluate large shRNA libraries. In this method, shRNA vectors are tagged with a unique 
oligonucleotide sequence before incorporation into cells, and then identified via PCR 
amplification and barcode sequencing. The understanding of gene function acquired by 
large-scale RNAi screens has greatly contributed to signaling pathway elucidation and 
drug target discovery in cancer and infectious diseases (Agaisse et al., 2005; Diehl et al., 
2014; Moffat and Sabatini, 2006). In addition, such pooled barcode shRNA screens have 
been performed both in culture and in animals (Blakely et al., 2011; Gargiulo et al., 
2014).  
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There is no pooled small molecule screening method for cell-based assays 
analogous to the pooled, RNAi screening technology. A major limiting factor is that 
multiple small molecules can easily penetrate one cell. The current paradigm is a one 
compound in one well approach, which provides a straightforward analysis, at the cost of 
being inefficient and prohibitively expensive to screen small molecule libraries without 
substantial automation (Kainkaryam and Woolf, 2009).  
Available approaches for small molecule pooling include adaptive strategies, 
where small pools of compounds (n = 5) are tested in one well. If the pooled collection 
induces the desired biological phenotype, each compound must next be tested 
individually to discover which compound to pursue. Without individual testing, 
deconvolution strategies can become complex because multiple compounds are acting on 
each cell in the well; the biological response may be a result of synergistic or additive 
effects of the combination of small molecules, leading to false positive hits (Kainkaryam 
and Woolf, 2009). Additionally, multiple compounds in a well can interact with each 
other or aggregate to antagonize an otherwise favorable biological interaction between 
target and individual lead compound. These factors lead to unavoidable false negative 
screening results. 
1.11 DNA-encoded libraries 
 DNA-encoded small molecule libraries have emerged as a method to screen pools 
of compounds against isolated protein targets (Brenner and Lerner, 1992). These libraries 
contain drug-like molecules tagged with DNA barcodes (Gartner et al., 2004). The 
covalently bound genetic component functions as a unique identifier of the small 
molecule. Extremely large libraries are most commonly built in a combinatorial fashion; 
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construction begins with one small chemical building block tagged with a small 
nucleotide sequence. As the second chemical building block is added, the DNA tag is 
also lengthened with an oligonucleotide sequence that encodes the new building block. 
These components are pooled, and subsequent building blocks with corresponding tags 
are added to quickly assemble large libraries. Pharmaceutical companies have 
implemented this strategy to build libraries that contain as many as 1 trillion unique 
molecules, each with DNA identifiers (Mullard, 2016). 
 Libraries can be interrogated using affinity-based techniques, where the entire 
library is incubated with a protein target equipped with a purification tag. After 
incubation in one well as a single mixture, the proteins are purified from the system; any 
small molecules bound to the protein will accompany the target throughout the 
purification. Because each small molecule isolated is linked to a DNA identifier, the 
barcodes from the purified system can be amplified and sequenced to reveal the ‘hit’ 
small molecules from the pool (Goodnow et al., 2017).  
This technique has been implemented to discover small molecules that potently 
interact with defined targets of interest (Franzini et al., 2015). An 800-million- member 
DNA-encoded library was assembled and screened to discover inhibitors of both p38 
MAP kinase and Aurora A kinase (Clark et al., 2009). Moreover, screening a DNA-
encoded macrocyclic library resulted in the discovery of a selective insulin-degrading 
enzyme inhibitor that can be developed as a strategy to treat type-2 diabetes and used to 
elucidate the role of the enzyme in glucose and hormone regulation (Maianti et al., 2014).  
DNA-encoded libraries have become a valuable screening strategy, with the 
potential to elucidate novel lead candidates for historically challenging targets (Buller et 
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al., 2009). By eliminating the need to distribute the protein target to millions of wells, as 
in arrayed HTS strategies, pooled screening of DNA-encoded libraries can yield results 
using unstable protein targets produced in minute quantities (Decurtins et al., 2016).  
DNA-encoded small molecule screening has distinct limitations when applied to 
drug discovery. Because the small molecule cannot cross the cellular membrane when 
conjugated to the DNA tag, this screening technique is restricted to biochemical, protein-
based methods or cell-based screens for proteins present on the cell surface. Additionally, 
the DNA barcode remains attached to the small molecule, which can alter the interaction 
of the small molecule with the protein target; false negative hits may arise because the 
small molecule’s activity cannot be assessed independent of the oligonucleotide 
modification (Franzini et al., 2014). The affinity-based purification step introduces 
additional challenges when interpreting screening results. Small molecules and their tag 
may bind to the purification column individually, without interacting with a protein, 
thereby introducing false positive ‘hits’. Finally, as with any affinity-based purification 
screening strategy, the purification tag added to the protein may interfere with the native 
protein structure, abrogating appropriate binding mode of the small molecule (Mullard, 
2016). 
1.12 Screening strategies in oncology 
 The ultimate objective for oncology therapeutic discovery is to create medicines 
that exclusively eradicate or reprogram malignant cells without adversely effecting 
normal cell populations. In order to achieve this differential drug activity, researchers 
often base therapeutic development on molecular aberrations that drive cancerous cells 
(Yap and Workman, 2012). The breakthrough development and success of the tyrosine 
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kinase inhibitor imatinib to treat BCR-ABL driven chronic myeloid leukemia confirmed 
the idea that small molecule therapies can effectively be designed to exploit specific 
genetic abnormalities known to drive malignant transformation in particular patient 
populations (Iqbal and Iqbal, 2014). Based on this prototype, target-based screening 
strategies have widely been implemented to create clinically successful therapies: e.g., 
sorafenib, a multi-kinase inhibitor discovered by a high-throughput small molecule 
screen for inhibitory activity against Raf1 kinase (Wilhelm et al., 2006); erlotinib, a non 
small cell lung cancer (NSCLC) treatment that inhibits the epidermal growth factor 
receptor (EGFR) (Dowell et al., 2005); and vemurafenib, for metastatic melanoma 
patients who possess the BRAF V600E mutation (Chapman et al., 2011). 
The significant challenge in designing therapies that address key molecular 
mechanisms responsible for tumorigenesis, however, is that cancer is an extremely 
heterogeneous disease; often there are unique physiologic profiles that occur within one 
patient, one tumor, or even in one cancer type (Welch, 2016). Because there is rarely one 
biological target that solely drives the phenotype of a specific cancer, there are very few 
efficacious ‘magic bullet’ type therapies, where a molecule designed to target one 
molecular abnormality observed in the cancer entirely cures the disease.  
Phenotypic profiling can be implemented as an alternate, or concurrent, approach 
to drug candidate selection. In this case, assay design is based on the biological 
characteristics of cancerous cells (unrestrained proliferation, resistance to cell death, 
evasion of growth suppressors, etc.) (Moffat et al., 2014). Therapeutic candidates 
screened using these assays are selected for further study based on their ability to elicit a 
specific biological response. Historically, the most common high-throughput phenotypic 
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screens for oncology therapeutics are based on cytotoxicity assays using human-derived 
cancer cell lines that demonstrate unconstrained, rapid growth. Lenalidomide, a structural 
derivative of thalidomide, was discovered to possess anticancer properties using 
cytotoxicity assays in the 1990s. Although efficacious to treat multiple myeloma, only 
recently was its mechanism of action related to antitumor activity understood (Lu et al., 
2014). Two histone deacetylase (HDAC) inhibitors, vorinostat (Grant et al., 2007) and 
romidepsin (Ganesan, 2016), were also both discovered purely using phenotypic 
screening methods, demonstrating the value of incorporating physiologically relevant 
parameters in the discovery of clinically efficacious oncology therapeutics. 
 
1.13 Evasion of apoptosis 
Apoptosis, a form of programmed cell death, is an essential biological process for 
both embryonic development and the maintenance of cellular homeostasis (Elmore, 
2007). The dysregualtion and evasion of cellular apoptosis is a main cause of 
tumorigenesis and chemotherapy resistance, and is consequently characterized as one of 
the six hallmarks of cancer (Hanahan and Weinberg, 2000). A popularized strategy by 
which to develop oncology therapeutics is to encourage this highly regulated process to 
promote cell death; either through the phenotypic discovery of apoptosis inducing 
compounds, or by directly designing a molecule to inhibit pro-survival biological 
machinery.  
Apoptosis is characterized by distinct morphological and biochemical changes 
including cell shrinkage, nuclear condensation and fragmentation, and plasma membrane 
blebbing (Ouyang et al., 2012). An evolutionarily conserved family of cysteine proteases, 
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known as caspases, are the central components of the apoptotic response and are largely 
responsible for these morphological changes (Hengartner, 2000). In most cells, caspases 
are widely expressed as inactive proenzymes. Upon apoptotic pathway stimulation, 
caspases are proteolytically activated to generate a cascade of biochemical events that 
irreversibly commit the cell to death (Riedl and Shi, 2004; Thornberry and Lazebnik, 
1998). The highly controlled death process cumulates with fragmentation of the cell into 
independent vacuoles known as ‘apoptotic bodies’, which are rapidly recognized and 
removed by phagocytes to prohibit an inflammatory cellular response (Taylor et al., 
2008).  
Apoptosis can be subdivided into two main mechanistic categories that both 
converge on caspase activation: (1) the extrinsic or death receptor pathway, and (2) the 
intrinsic or mitochondrial pathway. The extrinsic pathway begins when transmembrane 
receptors belonging to the tumor necrosis factor (TNF) superfamily (e.g., Fas, also known 
as APO1 or CD95, TNF receptor I (TNFR1), or TNF-related apoptosis-inducing ligand 
receptor 1 (TRAILR1, also known as DR4)) engage with their extracellular ligand 
counterpart (Ichim and Tait, 2016). Ligand binding induces a dimerization event that 
provokes recruitment of adaptor proteins such as FAS-associated death domain protein 
(FADD), creating a death-inducing signaling complex (DISC). DISC formation mediates 
the activation of initiator caspases 8 and 10, which proteolytically cleave and activate 
effector caspases 3 and 7, committing the cell to apoptosis (Nair et al., 2014). 
Multiple signal transduction pathways in normal and malignant cells converge on 
the B-cell lymphoma-2 (Bcl-2) family of proteins to police the intrinsic, or mitochondrial 
pathway, of apoptosis (Adams and Cory, 2007). In healthy cells, the pro-survival 
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proteins, (Bcl-2, Mcl-1, Bcl-XL, Bcl-w, and A1) bind to the effector proteins Bax and 
Bak, sequestering their pro-apoptotic function. Upon receipt of an intracellular damage 
signal, pro-apoptotic BH3-only proteins (Bad, Puma, Noxa, etc.) selectively insert their 
alpha helical BH3 domain into the hydrophobic groove of the pro-survival proteins, 
initiating their displacement from Bax and Bak. This release of Bax and Bak activates 
them for homo-oligmerization, which triggers mitochondrial outer membrane 
permeabilization to release pro-apoptotic factors, like cytochrome c, into the cytosol. 
Cytochrome c associates with apoptotic protease-activating factor 1 (APAF-1) and pro-
caspase 9 to assemble an apoptosome, which activates caspase 9 (Elmore, 2007). 
Activation of caspase 9, in turn, enables the cleavage and activation of the caspases 3 and 
7, which irreversibly commit the cell to death.  
Another model of Bax and Bak activation establishes a set of “activator” BH3-
only proteins that can directly bind to Bax and Bak. These BH3-only proteins are 
sequestered by pro-survival Bcl-2 proteins, and can be released from pro-survival 
proteins upon competitive displacement by the set of BH3-only “sensitizer” proteins 
(Westphal et al., 2014). In either model, cell death is the result of BH3-only proteins 
binding to pro-survival proteins to activate Bax and Bak. 
1.14 Caspases as a biomarker for apoptosis 
 Caspases, or cysteine-dependent aspartate-specific proteases, can be thought of as 
the central executioners that drive apoptosis, as the activation of these inert zymogens is 
an essential contributor to the cell death pathway (Li et al., 2014). The role of caspases in 
cell death was first studied in the nematode Caenorhabditis elegans, where the cysteine 
protease ced-3 was discovered through genetic analysis of cell-death defective (CED) 
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mutants to be required for cell death process related to development (Ola et al., 2011). 
The first mammalian homologs of ced-3, caspase-1 and caspase-2, were subsequently 
discovered to play important roles in apoptosis and inflammation, and since, over a dozen 
caspases have since been elucidated in humans, mammals, insects, worms, and hydra 
(Hengartner, 2000).  
 All known caspases possess an active site cysteine, and specifically cleave peptide 
substrates on the carboxy-terminal side of aspartic residues. This aspartate preference is a 
unique phenomenon among proteases (Poreba et al., 2013), yet caspases do show 
overlapping substrate specificity within the family. 
Caspase 3 is the most highly expressed activated member of the family during 
apoptosis, and the most readily active caspase -3/-7 cleavage motif is Asp-Glu-Val-Asp 
(DEVD) (McStay et al., 2008). Assays using fluorogenic substrates that include the 
DEVD sequence have been developed and broadly implemented as a reliable and 
convenient method to detect apoptosis in mammalian cell extracts or animal models of 
disease (Ding et al., 2015; Thornberry and Lazebnik, 1998; Timmer and Salvesen, 2007). 
This target specificity, combined with the rapid, reliable, and robust means of 
measurement, make caspases an attractive biomarker for apoptotic cell death. 
Caspases are most commonly present as inactive ‘pro-caspases’ that transform to 
the active, cleaved protease during apoptosis, and obligate the cell to death. This 
extremely apparent change in activity provides a detectable measure by which to assess 
drug intervention. Detection and quantification of cleaved caspase 3 is currently used as a 
proof of concept biomarker for oncology therapy by immunohistochemistry, ELISA, or 
fluorescent based flow cytometry assays (Ward et al., 2008). Careful consideration 
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should be taken to determine an appropriate time for analysis, as the kinetics of apoptosis 
differ based on cell type and the drug MOA and PKPD properties (Ward et al., 2008). 
 
1.15 FRET- based fluorescent probes 
A FRET (Fluorescence Resonance Energy Transfer) sensor can act as a reporter 
of protease activity, to allow for selection of compounds that induce specific protease 
activity (Edgington et al., 2011). The integrity of the FRET pair should be maintained in 
live cells and disrupted upon activation of a protease to yield a detectable change in 
fluorescence. 
For effective fluorescence quenching, FRET relies on three principles: (1) overlap 
between the emission spectrum of the donor fluorophore and the excitation spectra of the 
acceptor fluorophore, (2) a donor-acceptor pair distance of 1-10 nm, and (3) suitable 
orientation of the FRET pair for effective non-radiative, resonance transfer of energy 
(Nagy et al., 2006). The acceptor identity is not limited to small molecule organic, 
fluorescent quenchers; quantum dots, larger gold nanoparticles, and carbon allotropes 
also add to the library of effective quenching agents. 
Applications of FRET-based probing of cellular physiology are wide ranging. 
Because of the highly sensitive, distance dependent quenching effect, FRET pairs have 
been employed as a powerful technique to study real-time protein conformational 
changes and localization in living cells or biochemical assays (Sekar and Periasamy, 
2003). Proteins can be site-specifically labeled with minimally perturbing FRET pairs to 
dynamically examine protein folding or stability (Haney et al., 2015), protein-protein 
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interactions (VanEngelenburg and Palmer, 2008), or interactions of target molecules with 
proteins (Rowland et al., 2015).  
 
1.16 Targeted approach to apoptosis-inducing molecule 
discovery 
Observations associated with protein involvement in the intrinsic apoptosis 
pathway spawned the concept of the ‘BH3 mimetic’: a small molecule that acts as a BH3-
only protein, binding to the hydrophobic groove in the prosurvival proteins to obstruct 
their functional activity, thereby activating apoptosis (Becker et al., 2014). Each of the 
BH3-only proteins bind to the pro-survival proteins with varying specificity, defined by 
the electrostatic interactions between the BH3-region of the pro-apoptotic protein and the 
lipophilic binding groove created by the BH1, BH2, and BH3 regions of the pro-survival 
proteins (Chen et al., 2005). These observations suggest that apoptosis is regulated by the 
interactions between particular subsets of these proteins, and cell death can be initiated by 
inhibiting members of the prosurvival family. 
This approach was first successfully demonstrated in 2005 by Oltersdorf and 
coworkers at Abbot (now AbbVie) with the development of small molecule ABT-737 
(Oltersdorf et al., 2005) and later, its orally bioavailable analog, ABT-263 (navatioclax) 
(Tse et al., 2008), which are considered “Bad-like” BH3 mimetics because they 
selectively bind to pro-survival proteins Bcl-2, Bcl-XL, and Bcl-w (van Delft et al., 
2006). These compounds show clinical utility, but are often ineffective as a single agent 
for cancer treatment. Several studies have shown that Mcl-1 overexpression is a common 
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mechanism of chemoresistance to these small molecules, as well as frequently used anti-
cancer therapies vincristine (Wertz et al., 2011), paclitaxel (Wertz et al., 2011), and 
gemcitabine (Wei et al., 2008). Additionally, Mcl-1 has been identified as one of the most 
common genetic aberrations observed in human cancer (Beroukhim et al., 2010), 
including lung (Song et al., 2005), prostate (Krajewska et al., 1996), breast (Ding et al., 
2007), pancreatic (Miyamoto et al., 1999), ovarian and cervical cancers (Brotin et al., 
2010), as well as melanoma (Boisvert-Adamo et al., 2009) and leukemia (Derenne et al., 
2002). Thus, there is an intense interest in developing a potent and selective inhibitor of 
Mcl-1. 
Inspired by the discovery of ABT-737, strategies taken to elucidate small 
molecule BH3 mimetics that target Mcl-1 have been based on high-throughput screening 
or NMR-derived fragment library screens. In each case, the small molecules discovered 
suffer from one (or more) of three main issues 1) low to moderate potency for Mcl-1 
(Bernardo et al., 2010; Richard et al., 2013), 2) low to no efficacy demonstrated in vivo 
cellular studies, or a lack of cellular effectiveness completely (Petros et al., 2014; 
Varadarajan et al., 2013), or 3) insignificant selectivity for Mcl-1 over other pro-survival 
Bcl-2 family members (Friberg et al., 2013; Song et al., 2013; Tanaka et al., 2013). 
 
1.17 Overview of dissertation 
The current state of drug discovery often relies on a combination of phenotypic 
screening and target directed discovery approaches to produce a first-in-class therapy. 
Appropriately, these philosophically disparate screening paradigms should not be taken 
as completely independent paths on the way to discovering an optimized therapeutic 
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small molecule; instead, they can work synergistically so that phenotypic assays can be 
mechanistically informed, and the optimization of the small molecule can benefit from 
target-based approaches. Additionally, understanding the molecular mechanism of action 
of drugs is beneficial not only for drug efficacy and specificity, but also so that the 
appropriate patients receive effective treatment based on the molecular understanding of 
their disease. 
  This dissertation describes the studies towards developing a pooled screening 
strategy for small molecules in cellular contexts. Through an initial screen, we set to 
phenotypically profile small molecule biological activity in a pooled fashion, while 
simultaneously gain insight about an individual, active molecule’s mechanism of action. I 
first describe the design of the pooled screen and define the goals necessary for 
successful application. Next, I outline the steps taken and challenges encountered during 
the invention of each component of the technology. Finally, I discuss a computational, 
target-based approach to design small molecules appropriate for future applications of the 


















2.1  Introduction 
Therapeutic candidates often fail upon exposure to the complex physiology found 
in animal models and human patients, which are not captured in simple high-throughput 
tissue culture screening systems. In addition, the time and expense needed to assess the 
effects of large numbers of small molecules limits the number of compounds that can be 
tested, and adds to the time and cost required for discovery of drugs and probes.  
This problem of evaluating large numbers of reagents in physiologically relevant 
cell and animal models has been addressed for genetic reagents such as RNAi (Boutros 
and Ahringer, 2008), CRISPR (Zhou et al., 2014) and cDNA (Wan et al., 2006), by 
creating barcoded retroviral libraries that can be used to infect target cells in culture or in 
animal models. Using these tools, effective reagents can be selected and decoded using a 
rapid and inexpensive procedure compared to testing of individual reagents one at a time 
in an arrayed fashion. In order to more efficiently analyze small molecules, a pooled 
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approach would similarly be useful. Large scale pooling of small molecules is not 
possible, because all cells are exposed to each compound, creating uninterpretable effects 
of large mixtures of compounds. This problem was solved for genetic reagents by 
physically packaging each test reagent into separate viral particles, which can deliver one 
genetic reagent to each infected cell, when the multiplicity of infection (MOI) is suitably 
calibrated.  
Using fluorescent silica microparticle beads coated with carboxylate groups, we 
covalently attached three components to the bead surface—(1) small molecules to be 
assayed via a cleavable linker, (2) a fluorescent reporter and (3) a photocleavable barcode 
encoding the identity of each test small molecule. This chapter will focus on outlining the 
design of the system, as well as the rationale for selecting an appropriate bead system and 
fluorescent sensor of small molecule activity.  
 
2.2  Results 
2.2.1 Initial design of pooled small molecule screening technology 
We designed a microparticle-bead-based system that could deliver small 
molecules into cells and report on the identity of the small molecule tested and its cellular 
activity (Figure 2.1). Once taken up into cells, the beads were designed to release the 
small molecule either by disulfide bond cleavage or cleavage of a linker peptide by 
cellular proteases. We envisioned that a fluorescent reporter could indicate if the small 
molecule delivered to a particular cell was exerting a desired biological activity. For 
example, if a small molecule initiates apoptosis, executioner caspase 3 should be 
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activated; caspase 3 is known to cleave the DEVD amino acid sequence (Poreba et al., 
2013); other fluorescent peptide reporters could similarly report on the activity of other 
proteases in cells. A fluorescent reporter attached to beads was thus designed to detect 
caspase 3 activation; we would separate the bead from a fluorophore with the DEVD 
caspase substrate. Upon apoptotic pathway activation, the DEVD sequence would cleave 
to disconnect the fluorophore from the bead. Apoptotic activity would be designated by a 
loss of fluorescent signal from the bead. Those beads without the fluorescent signal could 
be harvested from the original, fluorescent population by fluorescence-activated cell 
sorting (FACS). Finally, an oligonucleotide, indicative of small molecule identity, is the 
third component attached to the bead. Upon bead collection, the identification tag would 












Figure 2.1 | Design of bead-based system for pooled screening of small molecules. (1) 
The technology, containing the covalently bound small molecule, identification tag, and 
activity reporter, is internalized by the cell. (2) Once inside the cell, the small molecule is 
released through the reduction of the disulfide bond linker. (3) The small molecule exists 
inside the cell without chemical modification. (4) If the small molecule causes apoptosis, 
activated caspases will cleave the DEVD peptide sequence connecting the fluorophore to 
the bead. (5) Loss of fluorophore results in absence of signal. (6) The activated system 
will be sorted based on this change in fluorescence, and the barcode sequenced to identify 
the small molecule that caused cell lethality. Red bead, silica microparticle; S-S, disulfide 
linker; blue square, lethal small molecule; green star, fluorescent dye. 
 
 31 
2.2.2  Selection of the bead component for technology delivery 
 We reasoned that during the course of a pooled small molecule screen, the beads 
must be harvested in order to sequence barcodes that encode the identity of the test 
compounds attached to each bead. The beads must thus be made of a material that does 
not affect cell viability, and that does not decompose upon cellular internalization or cell 
lysis. Additionally, the beads must be small enough to be adequately internalized by the 
cell, yet large enough to carry a suitable amount of each component (reporter, small 
molecule, identification tag) for detection. Our goal was to find a bead type that 
demonstrates sufficient cellular uptake with a maximum of functional handles for 
chemical synthesis.  
  Moreover, the surface of the beads must contain synthetic handles amenable to 
bioconjugation of DNA, peptides, and small molecules. Initial studies of carboxylate-
coated, polystyrene beads show that smaller beads (with 0.1 and 0.2 µm diameter) were 
taken up by virtually all HT-1080 fibrosarcoma cells after 6 hour incubation (Figure 2.2), 
but the surface area available and fluorescence intensity were less favorable for small 
molecule delivery and cellular tracking, respectively. Beads with a diameter of 1 µm 
exhibited a balance of size for conjugation and cellular uptake, so this size of beads were 
used for technology development. 
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Bead material considerations 
Although polystyrene is a biologically inert material compatible with cellular 
assays, Life Technologies’s FluoroSpheres include a fluorescent component that we 
 
Figure 2.2 | Cellular uptake of polystyrene beads. HT-1080 cells show uptake of 
polystyrene beads with differing diameter after 6 h incubation at 37 oC. Beads 1 µm 
in diameter were selected for technology development because they demonstrate 




discovered to not be chemically conjugated to the polystyrene polymer. Bead incubation 
with organic solvents (dimethylformamide, DMF, or dimethylsulfoxide, DMSO) resulted 
in the polystyrene matrix swelling to release the trapped fluorescent components.   
We turned our attention to silica microspheres, 1 µm in diameter, with hope that 
they would maintain their structure and fluorescence upon incubation with solvents 
necessary for chemical modification.  
 
 
Figure 2.3 | Fluorescence analysis of 1 µm silica beads. Flow cytometry data of 
beads (540 nm excitation/ 625 nm emission) show diverse solvents do not alter 




Microparticle fluorescence and structure were both preserved after incubation in 
dimethylsulfoxide (DMSO), dimethylformamide (DMF), ethanol, water, and 2-(N- 
morpholino)ethanesulfonic acid (MES) buffers, suggesting that silica beads are 
compatible with a variety of organic synthesis conditions, in contrast to the polystyrene 
microparticle material. Regardless of the solvent environment, the fluorescence intensity 
of the beads on the appropriate emission detection channel of a flow cytometer remained 
constant (Figure 2.3).  
Dynamic light scattering (DLS) was used to analyze the microparticle size 
distribution profile of beads (Figure 2.4). DLS measurements assess the scattering of a 
monochromatic light source by particles in a solution; the similar size distribution of each 
group of beads demonstrated bead stability across diverse solvents. Additionally, we 
found that the carboxylate functionality on these beads is compatible with bioconjugation 
reactions with oligonucleotides and peptides. 
 
Figure 2.4 | Silica bead diameter measurement. Dynamic Light Scattering 
(DLS) analysis of beads after 72 h incubation with diverse solvents shows no 
bead degradation.  
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Silica Bead biocompatibility  
 We envisioned that these silica particles would act as the delivery vehicle for the 
system. Given the robust solvent stability of silica microparticles and their compatibility 
with diverse synthetic organic chemistry reaction conditions, we next examined the 
biocompability of this material. Cell viability experiments with varying concentrations of 






Figure 2.5 | Biocompatibility of silica beads. Cell viability, measured by 
CellTiter-Glo- based luminescence assay of HT-1080 fibrosarcoma cells 
incubated for 72 h with red fluorescent silica beads. ATP presence, 
indicative of live cell population, was unaffected, regardless of bead 
concentration. 
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To evaluate the appropriate balance of these factors, we studied cellular uptake of 
fluorescent microparticles that were 1 µm in diameter in HT-1080 fibrosarcoma cells. 
Because the beads possess a fluorescence emission maximum at 625 nm, cells that 
internalized the beads showed an increase in fluorescence on the FL2 channel of the flow 
cytometer, which detects fluorescence emission of 585/40 nm (Figure 2.6). The 
fluorescence of 10,000 live HT-1080 cells without beads (n = 4) was examined as a 
control to develop a suitable gate on the bead emission detection channel of the flow 
cytometer versus the fluorescence emission of the reporter component (FITC, excitation 
488 nm, emission recorded on 535 nm channel) such that the gate encompassed 99.8 +/- 
0.2% of the population. The gate was applied to each sample, and was used to 
discriminate between cells without beads versus cells associated with fluorescent beads. 
Of the live cell population analyzed, 8.2 +/- 0.4% of cells did not take up a 1 µm bead 
after six-hour incubation (n = 3); this population did not show an increase in fluorescence 






Figure 2.6 | HT-1080 cells that internalize beads show increased fluorescence. 
Scatter plot of flow cytometry data. A gate of the live cell population before bead 
incubation was applied, and 10,000 events for each trial were recorded inside the 
gate. 92 +/- 0.40% of HT-1080 cells incubated with 1 µm diameter bead showed a 
99-fold average increase in 585/40 nm filter (FL2 detectable fluorescence), bead 
emission channel, over control population after 6 hours. 
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Uptake studies of bead with diverse human derived cell lines were completed to 
assess the applicability of silica bead delivery system (Figure 2.7). In addition to HT-
1080 fibrosarcoma cells, 293T human embryonic kidney and RKN ovarian cancer cell 
lines also internalized the 1 µm diameter beads. 
 
Figure 2.7 | Diverse cell lines show sufficient bead uptake. 1 µm diameter silica 
beads can be internalized by human cell lines derived from different tissues. HT-
1080 cells demonstrated the largest change in fluorescence, motivating our choice to 
use this cell line for assay development throughout technology assembly. 
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Successful implementation of the technology relies on the delivery of one type of 
small molecule per cell. Each bead would have only one type of small molecule 
conjugated to its surface; if only one bead is incorporated into one cell, we ensure that 
only type of one molecule is incorporated, even in the presence of a pool of small 
molecules. By adapting the multiplicity of infection concept from viral screening, a single 
bead could be delivered into individual cells (Figure 2.8), demonstrating the feasibility of 
the one compound/cell approach. 
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Figure 2.8 | Adjusting MOI allows for one bead per cell uptake rate. 10x Microscope image of 1 
µm beads incubated for 6 h in HT-1080 cells. After dilution, 9,000 beads / 200,000 HT-1080 showed 
uptake at a rate of one bead per one cell.  
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Confocal microscopy confirmed cellular internalization of these 1 µm diameter 
beads (Figure 2.9); thus, we determined that this size would be ideal for maximizing 




Figure 2.9 | Internalization of bead incubated with HT-1080 cells. Confocal Z-
stack image of HT-1080 cells incubated for 6 hours with 1 µm diameter silica beads 
show microparticle uptake. (i) Red bandpass filter shows fluorescent bead. (ii) 
Green bandpass filter shows no bead fluorescence bleedthrough. (iii) Transmitted 
light. (iv) DAPI. (v) Overlay. 
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2.2.3 Design and analysis of the fluorescent, loss-of-function reporter 
The goal of the fluorescent sensor is to report on the biological activity of the 
small molecule under investigation. The sensor for this system was designed to enable the 
selection of compounds that induce protease activity. Specifically, we set out to detect 
small molecules that cause cell death by activation of apoptosis, because this highly 
regulated form of cell death has well established biomarkers available for reliable 
detection. One well-evaluated biomarker of apoptosis is caspase 3 transformation from 
the pro-enzyme to active protease. This main executioner enzyme for apoptosis is known 
to cleave the DEVD peptide sequence. As such, we decided to separate the bead from the 
fluorophore with this DEVD peptide substrate (Figure 2.10). 
 
Figure 2.10 | Design of bead-fluorescent reporter. FITC dye was separated from 
the bead by a DEVD peptide chain. A rigid polyethylene glycol chain was included 
at the N-terminus of the peptide, to distance the cleavage site from the bead, 
allowing for protease accessibility. The PEG linker included a primary amine 
terminus, utilized for EDC coupling to carboxylate reactive sites on the bead 
surface.  
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Upon apoptosis induction with a lethal small molecule, we hypothesized active 
caspase 3 would detach the fluorophore from the bead though DEVD cleavage. A loss of 
fluorescent signal would distinguish the bead conjugated to a small molecule that caused 
apoptotic cell death from beads carrying inactive drug-like compounds; we hoped this 
loss of fluorescence would be distinguishable for sorting by fluorescence-activated cell 
sorting (FACS) so to allow for harvesting of the population for eventual barcode 
amplification and sequencing. Fluorescein isothiocyanate (FITC) was used as the 
fluorescent reporter of activity because it is a small molecule that would not greatly affect 
the size of the bead upon conjugation (unlike large fluorescent proteins, like GFP or 
RFP). Additionally, FITC has an excitation maximum of 490 nm, which corresponds 
with the 488 nm laser on our flow cytometer. Moreover, FITC has an emission 
wavelength of 535 nm, which is distinct from the bead fluorescence by microscopy and 
detectable by a unique emission channel on the flow cytometer. FITC is also a well-
studied dye, amenable to facile peptide conjugation and functions appropriately for our 
flow cytometry studies at a much lower price tag than fluorophores with similar 
excitation and emission spectra (i.e., Alexa dyes). 
The fluorescent sensor was designed to have a primary amine terminus, by which 
we used a robust N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) coupling for 
conjugation to the carboxylate handles coating the bead. The goal was to determine the 
lowest amount of peptide to the bead to maximize carboxylate ‘parking area’ for the 
barcode and small molecule components, yet a sufficient amount for clear detection of 
FITC fluorescence by flow cytometry for convenient distinction from unconjugated 
beads. In order to satisfy this requirement, it was necessary to include 0.001 equivalents 
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of fluorophore to 1 equivalent of carboxylate handle. Through the use of Beer’s Law, the 
reaction efficiency of conjugation was calculated to be consistently 80%, regardless of 




Figure 2.11 | Reaction efficiency of EDC conjugation reaction to create Bead-
FITC. Supernatant taken after completion of the EDC coupling reaction was fit to a 
Beer’s law curve. FITC concentration remaining in the supernatant was calculated 
using the molar absorptivity coefficient of the dye. Reaction efficiency was 
determined by subtracting the FITC concentration from the reaction without EDC 




Incubation of the Bead-FITC system did not induce cell death, as viability 
experiments were conducted using CellTiter Glo luminescence assays (Figure 2.5). This 
reagent was required for all bead-based cellular viability experiments, as it detects ATP 
presence. Alamar Blue or Presto Blue assays, where cellular viability is assessed by 




Figure 2.12 | FITC conjugation with silica bead. The primary amine terminus of the 
fluorescent reporter was covalently conjugated to the carboxylate coating on the bead 
by EDC coupling. Formation of the amide bond, and corresponding increase in 530 
nm fluorescence intensity, was detected by flow cytometry. The FITC had no 
observable impact on the bead fluorescence, denoted by the overlay in histograms of 
Bead and Bead-FITC intensity on the 585 nm emission axis. 
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silica beads. Additionally, the Bead-FITC pair demonstrated association with HT-1080 
cells after incubation at 37 oC for 6 hours.  
Subsequent attempts to cleave the fluorophore from the bead by caspase 3 
activation did not result in a detectable loss of signal, as there was no observable, distinct 
population after incubation with a purified, cleaved caspase 3 protein to enable its 





Figure 2.13 | Caspase 3 incubation with Bead-FITC. The Bead-FITC system was 
incubated with purified cleaved caspase 3 protein. Expected activity would be 
shown by a decrease in reporter emission intensity (x axis). After 2 h at 37 oC, there 
was no distinct loss of reporter fluorescence. 
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Fluorescent techniques have become a widely used and powerful tool to probe 
biological systems because of the sensitivity of their detection; a single fluorophore can 
generate many thousands of detectable photons. Moreover, the cycle of dye excitation 
and emission can be repeated many times for the same molecule. We attribute these 
fundamental characteristics of fluorescence to our inability to detect a loss of fluorescent 
signal; we hypothesize that the protease inefficiently cleaved the DEVD peptide, such 
that the residual, uncleaved dye had a fluorescence intensity comparable to the original, 
untouched Bead-FITC system (Figure 2.14). 




Figure 2.14| Design of new reporter system. Cartoon schematic representing our 
gain-of-sensor approach to use the sensitivity of fluorescence measurements to our 
advantage. 
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This observation motivated a new approach to the reporter design. Instead of 
scanning for a loss-of-fluorescence event to gauge biological activity, a gain-of-function 
event may be more sensitive for convenient measurement. To achieve this, the new 
reporter would include a small molecule quencher of fluorescent signal that would 
separate upon exposure to active proteases, yielding an increase in fluorescence 
detectable at assay completion (Figure 2.15). 
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Figure 2.15 | Design of bead-based small molecule screening technology. (1) The 
technology, containing the covalently bound small molecule, identification tag, and 
activity reporter, is internalized by the cell. (2) Once inside the cell, the small 
molecule is released through the reduction of the disulfide bond linker. (3) The 
small molecule exists inside the cell without chemical modification. (4) If the small 
molecule causes apoptosis, activated caspases will cleave the DEVD peptide 
sequence linking the fluorophore to the quencher. (5) Loss of quencher results in 
loss of FRET (gain of fluorescent signal). (6) The activated system will be sorted 
based on this change in fluorescence, and the barcode will be sequenced to identify 
the small molecule that caused cell lethality. Red bead, silica microparticle; S-S, 
disulfide linker; blue square, lethal small molecule; green star, fluorescent dye. 
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2.2.4  Design and analysis of FRET reporter 
To enable selection of small molecules that induce specific protease activity, the 
use of a FRET (Fluorescence Resonance Energy Transfer) sensor can be incorporated in 
our protease-reporter design (Edgington et al., 2011). The FRET phenomenon is a highly 
distance dependent effect, where the energy from an excited state fluorophore (the donor) 
is transferred to a nearby molecule (the acceptor), preventing the emission of a photon. 
The integrity of the FRET pair should be maintained in live cells and disrupted upon 
activation of a protease to yield a detectable change in fluorescence. We evaluated this 
concept initially with small molecules that cause cell death through apoptosis, continuing 
our study of caspase 3 activation as a biomarker. 
Taking advantage of the distance-dependent FRET requirement, we placed the 
DEVD substrate between a FITC-Dabcyl FRET pair to create ‘C3sensor’ (Figure 2.16). 
Upon caspase 3 activation, the peptide should be cleaved, to increase the distance from 
the donor fluorophore (FITC) to the acceptor chromophore (Dabcyl). FRET pair 
separation should result in increased fluorescence signal of the FITC dye. Indeed, we 
found that the fluorescence intensity of FITC increased 15 fold when incubated with 0.5 







Figure 2.16 | Design of Bead-C3Sensor. The design of the fluorescent reporter 
includes the red fluorescent bead, covered in carboxylate groups. An amide linkage 
attaches the fluorescent reporter of biological activity, which includes a 
polyethylene glycol spacer to avoid steric obstruction of protease accessibility by 
the bead, a lysine amino acid with a FITC fluorescent moiety conjugated to the 
sidechain, a GDEVDGSG peptide sequence that incorporates the activate caspase 3 
substrate, then finally a lysine residue differentiated with a dabcyl small molecule 
quencher attached to the sidechain. Molecular simulations reveal the fluorescent 
molecule is maximally separated from the dabcyl quencher by 25.54 angstroms, or 
roughly 2.5 nm—well within range to observe FRET quenching. 
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The FRET-caspase sensor was conjugated to silica microparticles by an amide 
linkage via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling of the 
primary amino terminus to the carboxylate-bead coating. We designated this covalently 
linked reporter-bead complex as ‘Bead-C3Sensor.’ To ensure that the peptide was 
covalently bound to the bead, we analyzed the zeta potential of the microparticles. Zeta 
potential measurements assess the electrostatic potential of the surface of particles 
suspended in aqueous solution by tracking the movement of charged particles across an 
 
 
Figure 2.17 | Incubation of FRET peptides with active caspase 3 protein. The 
DEVG peptide sequence was synthesized to act as a control for caspase 3 
cleavage; the exchange of an aspartic residue for a glycine residue eliminates the 
necessary amino acid after which the protease preferentially cleaves. The expected 
specificity was observed; a fluorescence fold change was increasingly observed 
for the DEVD FRET substrate, but absent in the control FRET pair. 
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applied electric field (Kirby, 2010). Similarly, charged particles in solution correlate to a 
large zeta potential, demonstrate stable colloidal dispersion, and low agglomeration of 
suspension. After conjugation, the zeta potential increased, demonstrating less repulsion 
between particles and thus supporting effective conjugation (Figure 2.18).  
To examine cellular internalization of the microparticle-peptide system, a peptide 
labeled with fluorescent FITC without the dabcyl quencher was used as a control, which 
we had previously studied and characterized (outlined in the prior section) (Figure 2.12). 
The FITC-only containing peptide is equivalent to the cleaved product of the bead with 
the FRET pair exposed to caspase 3, and shows high fluorescent intensity at two emission 
 
Figure 2.18 | Zeta potential measurement to assess covalent association of beads 
with sensor and barcode. Increase of zeta potential designates a loss of negative 
charge, observed upon sensor conjugation to the bead. An decrease in zeta potential 
relative to the Bead-C3Sensor occurs as a result of negatively charged 
oligonucleotides conjugated to the bead surface. 
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peaks corresponding to both the bead and the dye. This peptide fluorescence would be 
equivalent to 100% protease efficiency in cleaving each conjugated DEVD sequence. 
Fluorescence measurements demonstrated covalent attachment of the FITC-peptide to the 
bead, and confocal microscopy showed internalization of the peptide-bead system, Bead-
FITC (investigated in the following chapter, Figure 3.3).  
It is essential to distinguish the fluorescent reporter in the quenched FRET pair on 
beads from beads exposed to active caspase 3, so that flow cytometry can effectively 
separate each population. Ineffective separation would result in a high degree of false-
positive hits. Flow cytometry analysis of the Bead-C3Sensor conjugated pair showed 
comparable FITC fluorescence intensity to the bead alone (Figure 2.19). Both of these 
populations were distinct from the Bead-FITC conjugated pair, which showed a distinct 
increase in fluorescence intensity on the reporter fluorescence detection channel (Figure 
2.19).  
After the Bead-C3Sensor was exposed to purified, active caspase 3 protein, there 
was a distinct shift to higher reporter emission fluorescence intensity when compared to 
the original, uncleaved FRET state (Figure 2.20b). When a gate that encompasses 93 +/- 
2% of the native Bead-C3Sensor system (Figure 2.20a) was applied to the Bead-
C3Sensor exposed to active caspase 3 protein, 70 +/- 7 % of the beads have increased 
reporter fluorescence sufficient to fall outside of the gate (Figure 2.20b). That population 
is the target for harvesting, and the barcode of those samples could be sequenced to 





2.19 | Bead-C3Sensor demonstrates effective FRET. Flow cytometry data of the 
bead without peptide (red), the bead conjugated to FRET peptide: Bead-C3Sensor (dark 
blue) and the bead conjugated to the FITC peptide: Bead-FITC (light blue). 10,000 
events were recorded for 7 different samples of each population. The bead emission 
detection signal (y-axis) stayed consistent between all populations, demonstrating the 
bead fluorescence was not altered. The reporter emission detection channel (x-axis) 
registers the FITC signal, and was quenched upon dabcyl addition. F test between FITC 
and FRET populations on the reporter emission detection channel = 0.26 (n = 7). 
Cartoons representing structures of the Bead, Bead-FITC, and Bead-C3Sensor are 
displayed. 
Figure 2.12 | De 
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Figure 2.20 | Biochemical assay to assess FRET efficiency. (a) The FRET gate for FACS 
sorting. A gate (black) was included to encompass 93+/- 1.8% of the Bead-C3Sensor population 
(n = 8). (b) The FRET gate (black) is applied to the Bead-C3Sensor after 3 hour incubation with 
active caspase 3 protein. On average, the gate overlaps with 30 +/- 7.0% of the population (n = 
10). The remainder of the sample (blue) will be harvested for barcode sequencing. On average, 
we can expect to sequence 70% of the lethal small molecule population. Overlay of the Bead-
C3Sensor system with the Bead-C3Sensor + caspase 3 incubation shows a detectable difference 
in reporter fluorescence emission channel. (c) A cartoon representation of the biochemical assay. 
Bead-C3Sensor was subject to 1 unit of purified, active caspase 3 protein, which acts to cleave 
the DEVD sequence that bridges FRET pairs. An increase in reporter fluorescence is observed by 
a shift to higher fluorescence intensity on the 530 nm emission detector. 
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Cellular experiments were conducted, in which the Bead-FRET system was 
incubated with HT-1080 fibrosarcoma cells for 6 hours before addition of 1 µM 
staurosporine. Staurosporine is a broad kinase inhibitor well-established to induce 
apoptosis by caspase 3 activation (Johansson et al., 2003). After 24 hours, the entire flask 
was harvested, concentrated, and resuspended in lysis buffer to remove all beads from 
cells, as the final pooled screening procedure would require to accommodate barcode 
amplification. The entire sample was analyzed by flow cytometry. There was no observed 
change in the reporter fluorescence population of the beads (Figure 2.21). We 
hypothesize this is because the bead system does not have access to the cytosol, and 
therefore the reporter will not co-localize with caspases to report on their activation. This 
















Figure 2.21 | Incubation of bead FRET system with cells and analysis after 
apoptosis. Beads conjugated to the C3sensor and two distinct small molecule 
linkers were incubated with HT-1080 cells, and displayed cellular uptake by flow 
cytometry. After 6 h incubation with beads, the HT-1080 medium was exchanged 
for medium containing 1 µM staurosporine. After 24 h incubation, the entire sample 
was collected, lysed, and subjected to analysis by flow cytometry. A gate 
encompassing Bead-C3Sensor- small molecule linker (black) based on 585 nm vs 
530 nm fluorescence was applied to the scatterplot of the staurosporine incubated 
sample. A right shift (red) to higher 535 nm fluorescence intensity indicates the 
population where the C3Sensor was cleaved as a result of caspase 3 activation; there 
was no noticeable loss of FRET signal, denoting the C3Sensor did not report on the 
apoptosis that had occurred. 
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2.3 Discussion 
The technology design herein outlines our approach to create a pooled small 
molecule screening technology. The identification of an appropriate delivery vehicle and 
determination of a FRET-based component to report on the biological activity of the 
small molecule under examination were discussed. 
A 1 µm, red fluorescent silica bead coated with carboxylate groups demonstrated 
satisfactory fulfillment of each of our requirements initially outlined for an adequate 
delivery vehicle for the technology. The bead itself does not affect cell viability, yet the 
silica material and bead fluorescence can withstand a wide array of organic reaction 
conditions and cellular physiological changes that occur as a response to chemically 
induced lethality. A 1 µm diameter is small enough for cellular uptake, yet provides an 
acceptable surface area for chemical diversification. Bead fluorescence provides a 
convenient property for particle tracking throughout the duration of the assay and useful 
distinction from cellular debris for harvesting upon assay completion. The carboxylate 
moiety provides a robust handle, by which synthetic modification is convenient and 
amenable to oligonucleotides, peptides, and small molecules. 
Next, we designed a fluorescent reporter of small molecule activity. We learned 
that detection of a gain-of-fluorescence event was a more successful metric than the 
initial loss of signal approach, emphasizing the potential of fluorescence sensitivity to 
detect biomarkers of cellular processes. When conjugated to the bead, the FRET-based 
reporter shows a distinct signal after exposure to enzymatic activity specific to apoptotic 
cell death. The reporter design provides initial insight into the ‘hit’ small molecule’s 
mechanism of action, giving this pooled screen an additional, distinct advantage over 
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traditional phenotypic assays. Additional refinement is necessary for application to cell 
based assays, but the experiments outlined establish a foundation for further elaboration. 
As summarized in this study, this technology can be applied to discover cytotoxic 
small molecules that specifically initiate cell death by apoptosis. We envision that the 
system can be tuned and applied to wide-ranging, diverse cell models and biochemical 
processes as a drug and probe discovery tool. The peptide linker of the reporter can be 
modified to report on other proteases, protein-protein interactions, transcription, or other 
biological events.  
 
 
2.4  Methods 
Polystyrene Bead incubation with cells. 
FluoroSpheres Carboxylate-Modified Microspheres, Red fluorescent (580/605 nm) 2% 
solids, diameter ranging from 0.1 µm – 2 µm, were purchased from ThermoFisher 
(Waltham, MA, USA, Product Number F-8887). HT-1080 (fibrosarcoma) cells were 
obtained from American Type Culture Collection (Manassas, VA, ATCC CCL-121). HT-
1080 cells were grown in DMEM High-glucose medium supplemented with 1% non-
essential amino acids (Mediatech, Product Number 10-013-CM) 1% P/S, and 10% heat-
inactivated fetal bovine serum (FBS). All the cell lines were grown at 37 °C under 5% 
CO2 and harvested at 80% confluence for experiments. Uptake experiments were 
completed in 6 well plates (Corning costar (Corning, NY, 3516). 200,000 HT-1080 cells 
were plated per well and let adhere overnight at 37 °C under 5% CO2. Before use, beads 
were washed with deionized water twice by adding 1000 µL water to 20 µL beads, 
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sonicating (15 seconds), vortexing, centrifuging for 5 minutes at 14800 rpm (16162 xg) 
and removing the supernatant. 10 µL of 1:1000 dilution of beads to media were added to 
each well of cells. After six hour incubation with beads at 37 °C, the cells were washed 
twice with PBS, harvested with 0.25% Trypsin-EDTA (1X) Phenol red (Invitrogen 
(Carlsbad, CA, 25200-114)), resuspended in growth medium, and strained by a 70 µm 
filter (Fisher Scientific, 352350) into Eppendorf tubes for flow analysis. 
 
Flow Cytometry experiments. 
Flow cytometric analysis was assessed on an Accuri C6 Flow Cytometer with a 488 nm 
Laser. The 530/30nm filter (FL1) was used for FITC discrimination and the 585/40nm 
filter (FL2) was used for bead identification. Using a live cell gate on DMSO treated 
cells, 10,000 events were recorded for each population.  
 
Silica bead incubation with cells. 
Red (540/625 nm) fluorescent, non-magnetic, monodisperse, carboxylate coated 
screenCORE microspheres were purchased from Chemicell (Berlin, Product Number 
6101-1) HT-1080 (fibrosarcoma) cells were obtained from American Type Culture 
Collection (Manassas, VA, ATCC CCL-121). HT-1080 cells were grown in DMEM 
High-glucose medium supplemented with 1% non-essential amino acids (Mediatech, 
Product Number 10-013-CM) 1% P/S, and 10% heat-inactivated fetal bovine serum 
(FBS). All the cell lines were grown at 37 °C under 5% CO2 and harvested at 80% 
confluence for experiments. Uptake experiments were completed in 6 well plates 
(Corning costar (Corning, NY, 3516). 200,000 HT-1080 cells were plated per well and let 
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adhere overnight at 37 °C under 5% CO2. Before use, beads were washed with deionized 
water twice by adding 1000 µL water to 20 µL beads, sonicating (15 seconds), vortexing, 
centrifuging for 5 minutes at 14800 rpm (16,162 x g) and removing the supernatant. 10 
µL of 1:1000 dilution of beads to media were added to each well of cells. After six hour 
incubation with beads at 37 °C, the cells were washed twice with PBS, harvested with 
0.25% Trypsin-EDTA (1X) Phenol red (Invitrogen (Carlsbad, CA, 25200-114)), 
resuspended in growth medium, and strained by a 70 µm filter (Fisher Scientific, 352350) 
into Eppendorf tubes for flow analysis. 
 
Bead incubation with different solvents 
Beads were washed twice by adding 1000 µL deionized water to 20 µL beads, sonicating 
(15 seconds), vortexing, centrifuging at 14800 rpm (16162 xg) and removing the 
supernatant. Beads were resuspended in 20 µL deionized water by sonication, and 1 µL 
of the resulting suspension was added to 1000 µL solvent (DMSO, DMF, etc.). The 
mixture was vortexed, sonicated, and left to incubate at room temperature for 72 h before 
flow cytometry analysis and dynamic light scattering experiments. 
 
Confocal fluorescence imaging 
Coverslips with HT-1080 cells incubated with beads (procedure described above) were 
washed with PBS and fixed with 4% paraformaldehyde at room temperature for 10 
minutes. After 3 washes with PBS, the cover slips were mounted on slides using ProLong 
Diamond Antifade Mountant with DAPI (Thermo Fisher (Rochester, NY, P36966)). 
Confocal images were taken with a Zeiss AxioOberever LSM700 at 63x and the Z Stacks 
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were compressed with Zen software. Analysis was done using ImageJ (National Institutes 
of Health, Bethesda MD). All pictures are a single confocal section imaged eight to 
twelve times to reduce noise.  
 
Synthesis of Bead-FITC and Bead-FRET 
All chemicals were obtained from Sigma Aldrich and used without further purification. 
This procedure was performed open to the atmosphere. 20 µL beads (Chemicell (Berlin, 
Product Number 6101-1)) were washed with 0.1 M MES buffer (pH 6.3) by 
centrifugation at 14800 rpm (16,162 x g) for 5 min, removing the supernatant, re-
suspending in buffer, and centrifuging again. The bead pellet was re-suspended in 85 µL 
N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (10 µM in MES buffer), 0.68 µL 
peptide (5 mM, 0.001 equiv to carboxylate on bead surface), then 42.5 µL N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) (100 mM in MES buffer). The 
reaction was shaken at 37 °C overnight before washing five times with water, then four 
times with 0.5% Triton-X. Fluorescence of the supernatant of the final washing (494 nm 
excitation, 525 nm emission) was recorded to ensure no unconjugated fluorophore 
remained with the beads. 
The absorbance of bead-FITC-coupling reaction supernatant was measured at 494 
nm to assess peptide coupling efficiency. Concentration was calculated using the Beer-
Lambert law(Swinehart, 1962). % Coupling efficiency = ([FITC Reaction] – [FITC 
Supernatant]) / [FITC Reaction] x 100. 
 
Cell viability experiments 
 65 
Assay plates were prepared by adding 1,000 HT-1080 cells per well in 35 µL of growth 
media to opaque white 384 well plates (PerkinElmer (Waltham, MA, 6007688). After 
adhering to the plate overnight, growth medium was removed from the cells and replaced 
with 35 µL lethal molecule or beads in a two-fold dilution series. After 24 hours in the 
incubator, CellTiter-Glo Luminescent Cell Viability Assay (Promega (Madison, WI, 
G7573) was completed. Percent viability was calculated using cell luminescence intensity 
values determined from a Victor 3 plate reader (PerkinElmer).  
 
Biochemical assay for FRET detection: FRET peptide before conjugation to bead 
1.5 units of purified, active caspase 3 protein (Abcam (Cambridge, MA, ab52101)) were 
added to 1 µL 10 mM DEVD- FRET peptide or DEVG-FRET peptide (uncleavable 
control) and 97.5 µL Apo-One buffer (Promega (Madison, WI, G7791)). The solution 
was split into 3 wells of a Corning 385-well black with clear bottom plate (Corning, NY, 
Product number 3764), each containing 30 µL of the mixture and kept at 37 °C between 
timepoints. Before each time point analysis, the plate was shaken for 15 seconds. Wells 
were analyzed for fluorescence (490 ex/535 em) on the Tecan Infinite M100 PRO 
multimode reader (Mannedorf, Switzerland) with a constant gain set to 100. 
 
Biochemical assay for FRET detection: Bead-C3Sensor 
0.5 units of purified, active caspase 3 protein (Abcam (Cambridge, MA, ab52101)) were 
incubated with 2 µL of beads in 100 µL Apo-One buffer (Promega (Madison, WI, 
G7791)) for two hours at 37 °C. The beads were washed twice with MilliQ water and 











3.1  Introduction 
The third component of the pooled screening technology includes development of 
the small molecule identification tag. Barcoding by amplifying and sequencing 
oligonucleotides has demonstrated success in DNA encoded small molecule libraries 
(Clark, 2010) and pooled screens of genetic reagents (Wong et al., 2016). Based on this 
precedence, an oligonucleotide barcode could be applied and designed to fit the needs of 
the pooled small molecule screening technology. 
The success in the application of this pooled screening technology to cellular 
systems largely relies on the capability of the bead to efficiently deliver the small 
molecule once inside a cell and then effectively report on the compound’s activity. As the 
elaborated technology is applied to cellular systems, it is important to consider the 
mechanism by which the technology is internalized. 
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Macromolecules and other large particles enter the cell primarily through 
endocytosis. Endocytosis is an active process that involves an area of the plasma 
membrane engulfing the external material, then budding off to form a vesicle containing 
the ingested material. This uptake vesicle, or endosome, contains a mildly acidic pH that 
eventually matures to become a lysosome, which is an acidic compartment that houses 
hydrolytic enzymes to digest its components. 
Thus, a limiting step in achieving an effective biological based screening 
technology is to facilitate escape from the endosome to ensure cytosolic delivery of the 
system before its lysosomal degradation. This challenge is recognized, and strategies 
taken to address this obstacle are discussed. 
 
3.2  Results 
3.2.1 Barcode design 
For sufficient identification of one type of small molecule from a pool of diverse 
chemicals, each barcode must be unique to each small molecule structure, show no bias 
in PCR amplification, stay covalently bound to the bead throughout the assay, and be 
sequenced to reveal a statistical distribution of ‘hits’. We developed oligonucleotide 
barcodes consisting of 45 unique base pair sequence flanked by forward and reverse 
primer regions (Appendix A, Table A2). Each distinct barcode sequence used the same 
set of primers, so multiple ‘hit’ small molecules out of the pool could be equally 
amplified and identified. The primer design includes an overhang region with a sequence 
compatible with existing DNA sequencing technology. Next generation sequencing 
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strategies provide a scalable means to directly apply this prototype to large libraries of 
oligonucleotides. 
Prototype DNA barcodes were synthesized and attached to beads through an 
amide linkage after reaction with its terminal primary amine on the 5’ end. Next, a 
nitrobenzyl, photocleavable linker was included in the barcode design (Figure 3.1a), 
which we found necessary to increase PCR efficiency. Upon irradiation with near-UV 
light (300 – 350 nm range to avoid DNA damage), cleavage of the DNA from the bead 
was observed after 10 minutes (Figure 3.1b). This cleavable linker was included to make 
PCR amplification of the oligonucleotide more efficient after isolation of the bead, as we 
found that PCR amplification was inefficient on beads: lack of amplification was 
observed when the oligonucleotide remained bound to the bead and can likely be 
explained by steric hindrance of the bead to the polymerase. The bulky bead may block 
the polymerase from binding to the oligonucleotide, preventing DNA extension. Two 
unique barcodes were initially used for a proof of principle to ensure effective primer 
binding to more than one sequence (Figure 3.1b). Once the barcode was conjugated to 
the bead, the system was incubated for 24 h with the lysate of cells that were undergoing 
apoptosis. Despite protease activation and other environmental changes that occur during 
the programmed death pathway, the oligonucleotide was effectively PCR amplified after 
photo cleavage from the bead (Figure 3.1c). This suggests the bead-barcode conjugated 
pair can persist throughout the entirety of the screen for small molecule identification, a 
key feature of a pooled small molecule screening system.  
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Figure 3.1 | Small molecule identification tag, design and amplification. (a) Design of 
barcode component. (b) Electrophoresis DNA gel after PCR amplification of the barcode.  The 
photocleavable linker was necessary for adequate amplification.  Using similar thermocycler 
conditions and identical primers, barcodes of different sequences were amplified with similar 
efficiency. There is no bias observed for one sequence over the other. (c) Electrophoresis DNA 
gel after PCR amplification of the barcodes incubated with cell lysate.  A band at the appropriate 
molecular weight marker is observed, demonstrating that the oligonucleotide sequence is 
maintained throughout lysis conditions and exposure to enzymes and cellular components present 
during cell death by apoptosis. 
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3.2.2 Bead-Barcode-Sensor system synthesis and characterization  
The first step of integrating all of the components of the system involves 
differentiating a portion of the surface of the bead with a functionality to react with the 
small molecule. We sought a high concentration of each small molecule to be bound to 
each bead, to maximize the ultimate cellular concentration achieved. When using 0.5 
equivalents of mono-Boc protected diamine per one equivalent of carboxylate group on 
the bead surface, there is a large enough concentration of unreacted carboxylate handles 
on the bead for effective conjugation and detection of the barcode and fluorescent 
reporter, but the majority of chemical space on the bead surface will be unreactive to 
these moieties, having been coupled to the protected diamine. It is thus inert to the 
subsequent EDC couplings and reserved for small molecule attachment. Deprotection of 
the Boc moiety to reveal a primary amine was possible with concentrated trifluoroacetic 
acid because the silica bead withstands strong acid and the more sensitive groups 
(peptide, oligonucleotide) not yet attached. Facile coupling of 3-(2-
pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) to the newly 
differentiated bead surface yields a pyridine- disulfide moiety that withstands the 
chemistry to attach the oligo and fluorophore, yet will react during a simple and robust 
thiol-sulfide exchange reaction to attach the lethal small molecule to the bead in the last 
step. The disulfide bond attachment designed for release in the cytosol is established for 
future study of technology in cell culture 
Zeta potential measurements confirmed covalent coupling of both the sensor and 
the barcode to the bead during the one-pot EDC reaction. The addition of the 
oligonucleotide to the bead-peptide conjugate made the zeta potential slightly more 
 71 
negative (previous chapter, Figure 2.18)). Additionally, dynamic light scattering showed 









Figure 3.2 | Dynamic light scattering experiment shows size increase upon 
addition of the barcode to the bead.  
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Confocal microscopy showed internalization of this bead-dye-oligo reagent 
(Figure 3.3a and b), and that this system was not lethal to HT-1080 cells after 48 h 
incubation (Figure 3.4). Amplification of the barcode was possible after conjugation, 
demonstrating that simultaneous, one-pot coupling with the sensor, after first 
differentiating about half of the carboxylate groups on the bead to reserve enough space 
for eventual lethal molecule addition, did not affect ability for barcode sequencing. 
Additionally, caspase 3 protein incubation with the elaborated system showed detectable 




Figure 3.3 | Bead-FITC-Barcode internalization by HT-1080 cells. (a) Confocal microscopy internal 
slice of Z-stack image, after Bead-FITC-Barcode technology incubation with HT-1080 cells for 6 hours. (i) 
Bead fluorescence in red bandpass filter. (ii) FITC fluorescence of FITC-peptide conjugated to bead in 
green bandpass filter. (iii) Transmitted light. (iv) DAPI (v) Overlay. (vi) Full Z-stack overlay image. (b) 
Slices of Z-stack produced by confocal microscopy of Bead-FITC-Barcode technology with HT-1080 
incubation. Yellow overlay shows co-localization of Bead-FITC signal.  Outermost slices show no Bead 
presence, supporting the observation that the cell internalizes the bead. 
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3.2.3 Small molecule addition to complete system synthesis 
The final component of the small molecule pooled screening technology required 
is covalent attachment of test small molecules. The small molecules should detach from 
the bead only once the system is internalized into cells. We first examined the utility of 
the potentially glutathione-reductase-rich environment of the cytosol to employ a 
disulfide-bond linker to connect the bead to the small molecule (Figure 3.5a). Although a 
covalent bond is maintained outside of the cellular environment, once internalized, the 
disulfide bond should be reduced to cleave the small molecule from the cell. Once inside 
the cell, the small molecule should not contain any additional chemical modifications that 
can alter its biological activity.  
The lethal small molecule used for this proof of concept experiment was the 
microtubule inhibitor mertansine (DM1). DM1 was chosen because of its potency (4.6 
 
Figure 3.4 | Cell viability experiment with elaborated beads. HT-1080 cells incubated 
for 72 h with varying concentrations of bead conjugated to the barcode and fluorescent 
reporter show no decrease in cell viability. 
 75 
nM in HT-1080 cells) to induce apoptosis. Additionally, DM1 possesses a terminal thiol 
moiety in its active state, thus simplifying the model by eliminating the need for a self-
immolative linker. The chemistry used to covalently attach the known lethal molecule is 











Scheme 3.1 | Technology synthesis. Instillation of the handle to connect the small  
molecule is added first, followed by one-pot EDC conjugation of the fluorescent  
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To test the release of active small molecules in cells, we also synthesized a non-
cleavable, thioether linker using maleimide bioconjugation chemistry to control for 
disulfide bond reduction and release of the small molecule after bead uptake (Figure 
3.5b). However, we did not see cytotoxicity with either cleavable or non-cleavable small 
molecule-bead conjugated system (Figure 3.5d), suggesting cellular reductases could not 
release the compound from the disulfide linker.  
This observation, combined with the lack of FRET dissipation upon incubation 
with cells undergoing apoptosis, supports the notion that the bead system does not have 
access to the cytosol upon internalization.  
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Figure 3.5 | Design of small molecule component. (a) Structure of Bead-Disulfide linker-DM1. 
(b) Structure of Bead-thioether linker-DM1. (c) Dose response curve of HT-1080 when incubated 
with constant excess 1 µm, carboxylate coated silica beads (Chemicell) and unconjugated DM1 in 
two-fold dilution concentration increments. An EC50 of 4.6 nm was observed. (d) Upon conjugation 
of DM1 to the bead with a disulfide bond sensitive to cytosolic reduction (SPDP DM1, blue), no 
cell lethality was observed after 36 h treatment with HT-1080 cells. The thioether linker (BPMS 
DM1, red) was synthesized through maleimide Michael addition chemistry to serve as a stable 
conjugate control for disulfide bond cleavage, preventing DM1 liberation from the bead.  
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Extracellular particles must cross the cell’s plasma membrane in order to be 
internalized. This outer surface layer acts as a barrier separating interior cellular 
components from the environment. Large external particles are often trafficked across 
this barrier through a process called endocytosis. This active, actin-based process of 
ingestion begins by the movement of an area of the plasma membrane to surround the 
extracellular material. Eventually, the lipid bilayer completely engulfs the particle and 
buds off to create new intracellular vesicle containing the internalized matter. Pathways 
of endocytosis can be classified as (1) receptor-mediated endocytosis (which includes 
caveolae- and clathrin-mediated mechanisms) (2) pinocytosis, a non-specific pathway by 
which fluids and small particles are absorbed into small (~100 nm) vesicles, (3) 
macropinocytosis, the non-specific internalization of fluids and particles together and (4) 
phagocytosis, an energy dependent process specific to limited cell types (macrophages, 
etc.) and implemented to internalize foreign material larger than 0.5 µm (Doherty and 
McMahon, 2009). Physiochemical factors, including particle size, shape, and surface 
chemistry, as well as the cell type, determines the particle uptake, efficiency, and the 
mechanism of internalization (Oh and Park, 2014).  
 In biological environments, such as blood or culture cell medium, the surface 
charge of the microparticle dynamically changes; serum proteins in culture medium often 
coat the particle surface to influence the particle’s interaction with the cellular plasma 
membrane. Changes in surface charge in different solutions can also cause particle 
aggregation or agglomeration in solution, affecting uptake capabilities. Additionally, the 
shape and material of the particle influences cellular uptake, which also differs based on 
cell type. 
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Internalized microparticles traffic through vesicles called endosomes, which 
eventually mature through a series of fission and fusion events to lysosomes. Once inside 
the lysosome, internalized cargo is subject to degradation through exposure to an acidic 
environment rich in lysosomal hydrolases (Bright et al., 2016). We hypothesize the 
endosomal trapping of the silica bead prevents the technology from accessing the 
reductive environment of the cytosol, therefore preventing release of DM1 from the bead 
by disulfide reduction. Moreover, caspases activated as a result of apoptosis induction 
would be excluded from endosomal or liposomal compartments of the cell. Even if the 
small molecule transported by the bead were to escape the endosome/lysosome, activated 
caspases would not be able to access the confined bead to report on compound activity.  
We instead evaluated a cathepsin B and D cleavable linker to connect the lethal 
small molecule to the bead, which should release compounds from endosomal 
compartments when the bead system encounters cathepsin B or D. This lysosomal 
aspartic endopeptidase is localized in intracellular structures, such as endosomes, 
lysosomes, or phagosomes (Benes et al., 2008); as such, it should co-localize with the 
bead system if internalized by endocytosis.  
We conjugated the lethal molecule monomethyl auristatin E (MMAE) to beads 
via a cathepsin D cleavable linker (Figure 3.6). This system is based on the design of 
antibody drug conjugate (ADC) brentuximab vedotin; the structure of this drug includes 
an anti-CD30 antibody bound to MMAE by a protease-cleavable linker. Upon interaction 
with the CD30 receptor, the ADC is internalized and trafficked into lysosomes, by which 
active proteases release MMAE. This microtubule inhibitor induces cell death through 
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cell cycle arrest and apoptosis (van de Donk and Dhimolea, 2012). To apply this effective 
ADC design to our technology, we replaced the CD30 antibody with a 1 µm silica bead. 
After incubation of this bead system with HT-1080 cells, we observed 
cytotoxicity only when the cleavable compound was present (Figure 3.7b), thereby 
demonstrating that cathepsin-cleavable linkers are more effective for small molecule 
release, compared to disulfide linkers (Figure 3.7a). 
 
Figure 3.6 | Design of cathepsin D cleavable linker. Lethal molecule MMAE was 
linked to the silica bead by a cathepsin cleavable linker. The valine-citrulline 
dipeptide is the site of active protease cleavage; the p-aminobenzyloxycarbonyl is 
included as a self-immolative spacer for two reasons: (1) to facilitate access of the 
dipeptide to the enzyme active site and (2) to release the MMAE without 
modification, upon cathepsin cleavage. A maleimide terminus included on the 
dipeptide was reacted with thiol-differentiated moieties on the bead surface to 




This development established the final key element needed for a pooled small 
molecule screening system, including a suitable solid phase system that can be taken up 
by cells, a cleavable linker that gets released upon cellular uptake, a fluorescent reporter 
that can indicate compound activity, and an amplifiable barcode that can specify 
compound identity.  
 
Figure 3.7 | Cathepsin D cleavable linker shows effective release of lethal molecule 
upon HT-1080 cell incubation. (a) HT-1080 cells showed a decrease in viability when 
incubated with MMAE conjugated to the bead by a cathepsin cleavable linker; the 
disulfide bond linked DM1 did not demonstrate lethality, supporting our hypothesis that 
the bead does not have access to the reductive environment of the cytosol to enable lethal 
molecule release. (b) DMSO supernatant from the lethal molecule conjugated beads were 
tested with HT-1080 cells to ensure cells were only exposed to lethal molecules 
covalently bound to beads (a). No ambient, unconjugated MMAE or DM1 remained in 
solution at concentrations large enough to influence cell viability. 
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3.2.4 Investigation of endosomal escape mechanisms 
In order for the particle to reach cytosolic space, strategies to reduce the 
entrapment of commonly endocytosed large particles like transfection agents, liposomal 
drug delivery systems, carbon nanotubes, or cell penetrating peptides have been 
investigated.  
Endosome-disruption agents have been employed to increase bioavailability of 
peptide nucleic acids. Chloroquine is one such commonly used lysosomotropic agent. 
This small molecule has a weakly basic character that accumulates in endosomes and 
lysosomes after protonation, where it acts as an acidification agent. Through the 
accumulation of counter ions that accompany the influx of protons into the endosomal 
space, chloroquine encourages endosomal swelling and rupture to deliver entrapped 
cargo to the cytosolic space. Chloroquine has been efficacious in delivering endocytosed 
nucleic acid or protein cargos into the cytosolic environment during cellular assays (El-
Sayed et al., 2009). Often, however, the high concentrations of chloroquine necessary to 
facilitate endosomal release of internalized components induce cellular lethality (Wadia 
et al., 2004). Moreover, chloroquine co-treatment has shown no efficacy for delivery of 
biological macromolecules in vivo animal models due to its toxicity (El-Sayed et al., 
2009). These limitations deterred our investigation of lysosomotropic agents for 
applicability to our technology, as ambient addition of a small molecule known to exhibit 
pharmacological effects into the media of our assay would convolute our small molecule 
pooled screening results and significantly reduce technology efficiency.  
Cationic polymers, such as polyethyleneimine (PEI), poly-L-lysine (PLL), or 
chitosan, are commonly used as gene delivery agents or as nanoparticle coatings. This 
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modification contributes to improved cellular uptake of normally neutral nanoparticles 
(either made of polymers such as PLGA or inorganic materials such as carbon nanotubes 
or silica). The increased cationic nature induces particle attraction to the negatively 
charged cell surface, facilitating uptake by endocytosis. Once internalized and exposed to 
the acidic environment of the endosome, the amine groups within these polymers become 
protonated and behave as a buffer. This ‘proton sponge’ effect prevents further 
acidification and maturation of the organelle, yet leads to an influx of protons and counter 
anions. The resulting osmotic swelling destabilizes the endosomal membrane, eventually 
disrupting the structure to release all components into the cytosol (Ma, 2014). Cationic 
polymers exhibit increased cellular toxicity, limiting their use in physiological contexts. 
Particle modification with pH sensitive polymers provides an attractive solution to 
encourage endosomal escape with enhanced biocompatibility. The addition of imidazole 
groups to a particle surface decreases the degree of positive surface charge compared to 
cationic polymer coatings, yet exhibits a similar pH buffering capacity once the particle is 
internalized by endocytosis. This strategy has been widely employed for effective siRNA 
delivery (Mishra et al., 2006) (Gu et al., 2013) (Benns et al., 2000). 
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To enhance endosomal escape of our technology, we synthesized a histidine tag to 
add as a fourth component to our pooled screening system. Histidine amino acids are 
characterized by a sidechain containing an imidazole moiety, to which the conjugate acid 
form has a pKa of approximately 6.0; below a pH of 6, the imidazole ring would be 
mostly protonated (Figure 3.8). We hypothesized this attribute should sufficiently disrupt 
the endosomal entrapment of our bead system. The design of the tag included fourteen 
histidine amino acids separated from a primary amino group with a (PEG)3 spacer.  
 Using the Bead-SPDP-C3Sensor-barcode, three-component system, we 
conjugated increasing equivalents of the histidine tag using EDC bioconjugation 
chemistry, covalently linking the primary amino terminus of the tag with remaining 
carboxylate moieties coating the bead.  
 This system was incubated with HT-1080 cells for 16 hours before conducting 
uptake analysis by flow cytometry. There was sufficiently less cellular association of the 
 
Figure 3.8 | Incorporation of histidine tag to encourage endosomal escape. 
Installation of histidine moieties to the silica bead could facilitate cytosolic access of 
endocytosed particles. 
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histidine-containing bead with analyzed cells than beads without the added peptide, 
signified by the low population with increased fluorescence intensity on the 585 nm 
emission, bead detection channel (Figure 3.9). 
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 To overcome the uptake barrier, further tuning of the equivalents of histidine 
should be investigated. The addition of separate, positively charged moieties to the bead 
surface may assist uptake (Salatin et al., 2015), but will also complicate the synthesis of 
 
Figure 3.9 | Uptake analysis of total system with histidine peptide. (a) Complete 
system, with bead conjugated to C3Sensor, Barcode, and small molecule with two 
different linkers (designated in legend by BPMS or SPDP), were incubated with HT-1080 
cells for 16 h. Bead association with cells was designated by the shift to higher bead 
fluorescence intensity (585 nm emission axis). Upon addition of the histidine tag, Bead-
Barcode-C3Sensor association with cells decreased after 16 h incubation with HT-1080 
cells, when compared to the level of uptake observed in the absence of the covalently 
bound histidine component. 
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the system; this avenue was not immediately pursued. Alternative syntheses of histidine-
rich peptides could include cell penetrating peptide (CPP, also known as protein 
transduction domain, PTD) sequences. These peptide sequences are known to overcome 
the lipophilic, cell membrane barrier and facilitate internalization of bulky cargos such as 
liposomes, pDNA, oligonucleotides, or proteins. A common CPP implemented for 
increased macroparticle uptake is the TAT peptide, derived from the trans-activator of 
transcription of the human immunodeficiency virus (Bechara and Sagan, 2013). The 
sequence of this peptide is GRKKRRQRRR (Brooks et al., 2005); in order to be 
productively applied to our system, the peptide should be conjugated after the EDC 
couplings of the reporter and barcode to avoid reaction of its two lysine sidechains. 
Several studies have shown that the use of these peptides increase cellular uptake 
of macromolecules, but have had little influence on the endosomal escape when linked to 
bulky cargos (El-Sayed et al., 2009). An example of one peptide applicable to our system 
that may include both cell penetrating ability and a pH sensitive endosomal escape unit 
may look like NH2-(PEG)3-HHHH-GRKKRRQRRR; this has an appropriate amino 
terminus for EDC conjugation to our carboxylate coated bead, separated from the peptide 
sequence with a 9-carbon, polyethylene glycol, rigid spacer. This spacer is included to 
distance the primary amine terminus from the peptide, making the reactive moiety 
extremely accessible for prompt EDC coupling; presumably, the primary amine 
sidechains present in the lysine residues are more sterically hindered, making their 
reaction to form the amide kinetically unfavorable. The histidine unit is included as a 
lysosomotropic agent to facilitate cytosolic delivery of the bead, while the TAT 
component would assist its cellular uptake. Alternative approaches include replacing 
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TAT in our design with the CPP Arg-9 (peptide sequence: RRRRRRRRR) penetratin-
Arg (peptide sequence: RQIRIWFQNRRMRWRR, where the lysines of penetratin are 
substituted with arginine residues), aiming to discover the CPP that offers an optimal 
balance between endosomal escape capability and bead coupling efficiency.  
 
3.3 Discussion 
The development of the barcode and the protease-cleavable small molecule linker 
established the final key elements needed for a pooled small molecule screening system. 
This technology includes a suitable solid phase system that can be taken up by cells, a 
cleavable linker that gets released upon cellular uptake, a fluorescent reporter that can 
indicate compound activity, and an amplifiable barcode that can specify compound 
identity.  
The barcode is compatible with deep sequencing technology, so that a statistical 
distribution of small molecules can be determined from the pooled assay, thus reducing 
the ‘false positive’ hit molecules from the screen. The barcode does not affect the ability 
of the bead to be taken up by HT-1080 cells, stays with the bead throughout the duration 
of the assay, and can be amplified after incubation with cells undergoing death. 
The conjugation of mertansine to the bead system requires thiol-sulfide exchange 
chemistry, but covalent attachment of the small molecule to the bead has been effective 
using maleimide chemistry or NHS-reactive linkers to expand the scope of reactive 
moieties on the small molecule. The ability to use simple, robust bioconjugation 
chemistry to conjugate diverse linkers to the bead system enhances the number of small 
molecules that can be screened in this type of system.  
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Future improvements of this technology are ongoing. To address applicability to a 
broader chemical library, we have plans to explore the usage of a self-immolative linker 
to attach the small molecule via the disulfide bond. After the disulfide bond is reduced, 
the terminal thiol can participate in a nucleophilic substitution reaction with the 
carbamate to form a five-membered ring; this releases the amine-containing small 
molecule, in its original state, without any chemical modification. Small molecules 
included in the library must include a reactive handle by which to conjugate the 
technology, which we acknowledge as a screening limitation. While this disulfide system 
was not effective at releasing compounds under the conditions we used, it might be 
possible to engineer cells overexpressing specific reductases that can cleave such a linker. 
We found that a cathepsin-cleavable linker was more readily used in HT-1080 cells, 
suggesting that this may be a simpler release mechanism.  
Additional strategies to encourage endosomal escape can be pursued. Another 
approach of interest involves the photochemical disruption of the endosomal membrane. 
Photochemical internalization (PCI) methods involve the use of small molecule 
photosensitizers (disulfonated tetraphenyl porphine (TPPS4), disulfonated tetraphenyl 
chlorin (TPcS2a) (Berg et al., 2011), aluminum phthalocyanine disulfonate (AlPcS2A), or 
dendrimer phthalocyanine (DPc)) that localize primarily in the membranes of endosomes 
and lysosomes. Upon exposure to light of an appropriate wavelength, these agents 
produce singlet reactive oxygen species that disrupt and destroy the endosomal/lysosomal 
membrane, thereby liberating entrapped contents into the cytosol. These reagents do 
show in vivo efficacy, as many have been successfully evaluated to enhance antibody 
drug conjugate activity in animal models of cancer (Bostad et al., 2015) (Selbo et al., 
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2015). Co-treatment of these small molecules with our established technology may 
provide an attractive method by which to reduce endosomal entrapment of our 1 µm 
silica-bead-based technology.  It is essential, however, that the wavelength necessary to 
activate the PCI does not interfere with the photocleavable linker that attaches the DNA 
barcode to the bead; for this reason, PCI reagents excited by a homogeneous red light 
source of 652 nm emission may show greater compatibility with our screening design 
than those excited with a blue, 410-435 nm light. 
Ultimately, we suggest that further optimization and diversification of the 
components of the system may have numerous applications drug discovery and allow for 




Beads were exposed to 365 nm light for 10 minutes for PC linker cleavage. The beads 
were centrifuged at 14800 rpm for 5 minutes, and 1 µL of the supernatant was removed 
for PCR amplification. Phusion Hi-Fidelity DNA polymerase (New England Biolabs) 
was used with primer pair CEY_TruSeq_RPI1: CEY_TruSeq_RP1 (Sequence provided 
in Supplementary Data). 
Confocal fluorescence imaging 
Coverslips with HT-1080 cells incubated with beads (procedure described above) were 
washed with PBS and fixed with 4% paraformaldehyde at room temperature for 10 
minutes. After 3 washes with PBS, the cover slips were mounted on slides using ProLong 
Diamond Antifade Mountant with DAPI (Thermo Fisher (Rochester, NY, P36966)). 
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Confocal images were taken with a Zeiss AxioOberever LSM700 at 63x and the Z Stacks 
were compressed with Zen software. Analysis was done using ImageJ (National Institutes 
of Health, Bethesda MD). All pictures are single confocal section imaged eight to twelve 
times to reduce noise.  
 
Cell viability experiments 
Assay plates were prepared by adding 1,000 HT-1080 cells per well in 35 µL of growth 
media to opaque white 384 well plates (PerkinElmer (Waltham, MA, 6007688). After 
adhering to the plate overnight, growth medium was removed from the cells and replaced 
with 35 µL lethal molecule or beads in a two-fold dilution series. After 24 hours in the 
incubator, CellTiter-Glo Luminescent Cell Viability Assay (Promega (Madison, WI, 
G7573) was completed. Percent viability was calculated using cell luminescence intensity 
values determined from a Victor 3 plate reader (PerkinElmer).  
 
Bead characterization 
Microparticle size and zeta potential were measured on a Malvern Zetasizer Nano ZS 
(Malvern, United Kingdom). For all measurements, microparticles were diluted 1:1000 in 
MilliQ water at neutral pH. The reported diameters are the average of three 
measurements, where each measurement comprises at least 10 acquisitions. The zeta 
potential was calculated according to the Smoluchowski approximation (Sze et al., 2003). 
 
Technology synthesis 
All chemicals were obtained from Sigma Aldrich and used without further purification. 
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All peptides were synthesized by LifeTein (Somerset, NJ). Oligonucleotides were 
synthesized by Integrated DNA Technologies (Coralville, IO). Peptide and 
oligonucleotide sequences are detailed in Supplementary Tables 1 and 2. This procedure 
was performed open to the atmosphere. 20 µL beads (Chemicell (Berlin, Product Number 
6101-1)) were washed with 0.1 M MES buffer (pH 6.3) by centrifugation at 14800 rpm 
(16162 xg) for 5 min, removing the supernatant, re-suspending in buffer, and centrifuging 
again. The bead pellet was re-suspended in 85 µL N-Hydroxysulfosuccinimide sodium 
salt (sulfo-NHS) (20 mM in MES buffer), 8.5 µL N-Boc- 2,2′-
(ethylenedioxy)diethylamine (50 mM, 0.5 equiv to carboxylate on bead surface), then 
42.5 µL N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) (100 mM in MES 
buffer). The reaction was stirred overnight at 37 °C before Boc-deprotection with 1000 
µL 1:1 water: trifluoroacetic acid. After 30 minutes, the reaction was washed six times by 
centrifugation and bead re-suspension as described above. To the differentiated beads, 3-
(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP, 17 µL, 10 mM) was 
coupled by addition of 42.5 µL EDC (100 mM in MES buffer). The reaction was allowed 
to stir overnight at 37 °C before washing six times. The bead pellet was re-suspended in 
85 µL N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (10 µM in MES buffer), 0.68 
µL peptide (5 mM, 0.001 equiv to carboxylate on bead surface), 18 µL oligonucleotide 
(0.1 mM solution) then 42.5 µL N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) 
(100 mM in MES buffer). The reaction was shaken at 37 °C overnight before washing 
five times with water, then four times with 0.5% Triton-X. Fluorescence of the 
supernatant of the final washing (494 nm excitation, 525 nm emission) was recorded to 
ensure there no unconjugated fluorophore remained with the beads. PCR reactions 
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(procedure described below) of the final washing supernatant were completed to ensure 
no uncoupled barcode remained. Excess mertansine (DM1, Medchem Express, 
Monmouth Junction, New Jersey, Serial number G01432) (10 mM in DMSO, 17 µL) was 
added to the bead pellet for final coupling, shaken at 37 °C overnight before washing five 
times with DMSO. The final system was suspended in 20 µL DMSO (1 µL DMSO per 1 
µL bead from stock solution).  
 
Synthesis of Bead-Thioether-DM1 control 
All chemicals were obtained from Sigma Aldrich and used without further purification. 
This procedure was performed open to the atmosphere. 20 µL beads (Chemicell (Berlin, 
Product Number 6101-1)) were washed with 0.1 M MES buffer (pH 6.3) by 
centrifugation at 14800 rpm (16162 xg) for 5 min, removing the supernatant, re-
suspending in buffer, and centrifuging again. The bead pellet was re-suspended in 85 µL 
N-Hydroxysulfosuccinimide sodium salt (sulfo-NHS) (20 mM in MES buffer), 8.5 µL N-
Boc- 2,2′-(ethylenedioxy)diethylamine (50 mM, 0.5 equiv to carboxylate on bead 
surface), then 42.5 µL N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) (100 
mM in MES buffer). The reaction was stirred overnight at 37 °C before Boc-deprotection 
with 1000 µL 1:1 water: trifluoroacetic acid. After 30 minutes, the reaction was washed 
six times by centrifugation and bead re-suspension as described above. To the 
differentiated beads, N-ß-maleimidopropyl-oxysuccinimide ester (BPMS, Thermo Fisher 
Scientific, Grand Island, NY, Catalog number 22298, 17 µL, 10 mM) was coupled by 
addition of 42.5 µL EDC (100 mM in MES buffer). The reaction was allowed to stir 
overnight at 37 °C before washing six times. Excess mertansine (DM1, Medchem 
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Express, Monmouth Junction, New Jersey USA, Serial number G01432) (10 mM in 
DMSO, 17 µL) was added to the bead pellet for final coupling, shaken at 37 °C overnight 
before washing five times with DMSO. The final system was suspended in 20 µL DMSO 
(1 µL DMSO per 1 µL bead from stock solution).  
 
Synthesis of Bead-Cathepsin D cleavable linker- monomethyl auristatin E 
All chemicals were obtained from Sigma Aldrich and used without further purification. 
This procedure was performed open to the atmosphere. 20 µL beads (Chemicell (Berlin, 
Product Number 6101-1)) were washed with 0.1 M MES buffer (pH 6.3) by 
centrifugation at 14800 rpm (16162 x g) for 5 min, removing the supernatant, re-
suspending in buffer, and centrifuging again. The bead pellet was re-suspended in 85 µL 
N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (20 mM in MES buffer), 8.5 µL 
Boc- 2,2′-(ethylenedioxy)diethylamine (50 mM, 0.5 equiv to carboxylate on bead 
surface), then 42.5 µL N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) (100 
mM in MES buffer). The reaction was stirred overnight at 37 °C before Boc-deprotection 
with 1000 µL 1:1 water: trifluoroacetic acid. After 30 minutes, the reaction was washed 
six times by centrifugation and bead re-suspension as described above. The differentiated 
beads and 42.5 µL EDC (100 mM in MES buffer) were added to a solution of 3-
Mercaptopropionic Acid (17 µL, 10 mM) and 85 µL N-Hydroxysulfosuccinimide sodium 
salt (sulfo-NHS) (20 mM in MES buffer). The reaction was allowed to stir overnight at 
37 °C before washing six times. The beads were resuspended in 50 µL DMSO and excess 
maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate 
(MC-Val-Cit-BAP-PNP) (Accela Chemicals, San Diego, California, Compound ID 
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SY034490) was added to the reaction. The reaction was shaken at 37 °C overnight before 
washing five times with DMSO. To the beads was added excess monomethyl auristatin E 
(MMAE, Medchem Express, Monmouth Junction, New Jersey USA, Catalog number 
HY-15162) in DMSO. The reaction was shaken at 37 °C overnight before washing five 

















 All protein members of the Bcl-2 family share one or more of the Bcl-2 homology 
(BH) domains, and are essential regulators of the intrinsic apoptotic pathway. Some 
protein members of the Bcl-2 family work to promote apoptosis, while other members 
function to inhibit this cell death pathway; the imbalance between pro- and anti-apoptotic 
Bcl-2 proteins to shift equilibrium towards cell survival is a key mechanism in 
tumorigenisis and chemotherapeutic resistance (for additional pathway biology, see 
sections 1.13 and 1.16).  
Small molecule inhibitors designed to mimic BH3-only protein binding to Bcl-2, 
Bcl-W and Bcl-XL (ABT-263, navitoclax) or solely Bcl-2 (ABT-199, venetoclax) have 
demonstrated clinical efficacy. Although these examples validate the ‘BH3-mimetic’ 
concept as an attractive targeted approach to induce apoptosis in cancers, these 
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compounds are subject to chemoresistance through overexpression of Mcl-1, a Bcl-2 pro-
survival member unaffected by the aforementioned small molecule inhibitors (Walensky, 
2012).  
Thus, the longstanding challenge has been to develop a BH3-mimetic to target 
Mcl-1 that possesses 1) biological activity dependent on Bax/Bak, 2) low nanomolar 
affinity for the target protein, 3) cytotoxic activity correlated with cellular Bcl-2 protein 
family levels, and 4) in vivo treatment that triggers relevant biomarkers indicative of Bcl-
2 family antagonists (Lessene et al., 2008). The discovery of such a small molecule that 
specifically targets Mcl-1 would have outstanding utility in the clinical setting as a cancer 
therapeutic, and the tactic upon which the molecule is discovered would lay the 
groundwork for drugging diverse protein-protein interactions. To reduce side effects 
observed by targeting multiple members of the anti-apoptotic Bcl-2 family (Bcl-XL 
inhibition is associated with thrombocytopenia), our goal stands to tailor a drug that 
exclusively inhibits Mcl-1. To date, there is one such inhibitor (S63845) that shows on-
target efficacy to induce apoptosis in Mcl-1 dependent cancer cells in vitro and in vivo, 
but its clinical utility has yet to be investigated (Kotschy et al., 2016). This molecule, and 
other small molecules (Friberg et al., 2013) and stapled peptides (Cohen et al., 2012) that 
have shown Mcl-1 inhibition through protein-based assays, have been discovered using 
NMR-based fragment screening strategies. Subsequent SAR studies were guided by 
three-dimensional x-ray crystal structures of the bound fragments inside the Mcl-1 
protein. 
Inspired by the therapeutic relevance of Mcl-1, we set out to examine the 
applicability of alternate target-based screening strategies to more efficiently discover a 
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novel Mcl-1 inhibitor. We examined computer-aided drug design (CADD) screening of 
in silico libraries of compounds, aiming to generate BH3 mimetic small molecules that 
could be rationally elaborated upon to optimize binding affinity, target specificity, and 
ADME properties. High-throughput screening of in silico small molecule libraries would 
provide a time- and cost-effective alternative to physically screening thousands of 
chemical compounds for activity. Moreover, computational docking strategies illustrate 
the ideal pose assumed by the small molecule when interacting with the specified binding 
pocket, significantly aiding eventual lead compound optimization efforts.  
 
4.2 Results 
4.2.1. Protein structure selection 
 Three-dimensional structures of myeloid cell leukemia 1 (Mcl-1) have been 
experimentally elucidated by x-ray crystallography; these structural biology data drove 
our computational screen. Using the RCSB Protein Data Bank, we obtained a crystal 
structure of an inhibitor-bound Mcl-1 complex with 2.4 Å resolution (4HW3). We chose 
to use a crystal structure with a bound inhibitor for two main reasons: (1) the bound 
molecule has a known Ki of 0.32 µM (Friberg et al., 2013); removing and then re-
docking the bound molecule in the designated target site to obtain a docking score would 
provide a scoring benchmark upon which to compare new small molecules, and (2) the 
ability to crystalize the protein-inhibitor complex gives an accurate picture of where the 
small molecule has a large probability of binding. The crystal structure chosen supports 
the ability of small molecules to interact directly with the BH3 domain to out-compete 
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BH3-only proteins and peptides for Mcl-1; small molecules that induce allosteric effects 
that render the protein inactive were not observed in the structural database, and therefore 
not considered during our screen. By examining the protein structure, it is clear that a 
deep hydrophobic pocket in the BH3 domain of Mcl-1 would accommodate small 
molecule binding (Figure 4.1) 
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Figure 4.1 | Mcl-1 protein structures. The Mcl-1 protein structures are displayed with a 
surface demonstrating regions of hydrophobicity; blue regions depict hydrophilic 
residues, while yellow portions demonstrate lipophilic areas of the protein surface. (a) 
BH3-only peptide bound to the BH3 region of Mcl-1. (b) Re-docked structure of known 
inhibitor assumes similar binding pose as the crystalized protein-inhibitor structure. The 
site shown with the small molecule bound inside the BH3 region of Mcl-1 is the location 
of the center of our grid, in which all libraries of in silico small molecules were docked. 











4.2.2  In silico ligand library screening 
Next, we compiled a computational library consisting of ~5 million commercially 
available small molecules found in the inventories of eight different vendors (Asinex, 
Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge, and TimTec). The goal of this 
initial high-throughput computational screen was to examine a large amount of chemical 
space in order to identify promising molecular scaffolds. As such, before docking, the 
large library was filtered for ‘fragment-like’ properties: including LogP < 3, hydrogen 
bond acceptors ≤ 3, hydrogen bond donors ≤ 3, molecular weight < 300, aqueous 
solubility >0.5 mM were applied to whittle the library to 604,457 small molecules. After 
identification, rationally elaborating upon the structure of these core scaffolds would 
enhance target affinity. 
After preparing both the ligand library and protein for virtual screening, all small 
molecules were docked using Maestro SP (Schrodinger) into the BH3 domain of Mcl-1 
and each ligand’s docking pose was scored. This empirical scoring function (GlideScore) 
is designed to approximate ligand binding free energy of the compound for the target; the 
more negative the score, the tighter the interactions. When re-docked into the crystal 
structure after extraction, molecule 60 assumed a similar pose to the crystalized model; 
this orientation demonstrated a Glide score of -8.3; we postulated that ligands with a 
score equal to or better than -8.5 may have similar or better binding affinity for Mcl-1. 
1,054 compounds fit these criteria. These molecules were clustered based on a Tanimoto 
coefficient of 0.54 to represent a broad area of chemical diversity, and 96 of these 
commercially available compounds were ordered for biochemical testing. 
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4.2.3  Fluorescence polarization assay 
A fluorescence polarization (FP) competition assay was used as the method to 
experimentally determine the affinity of these ligands for Mcl-1. When small fluorescent 
molecules in solution are excited with plane-polarized light, their Brownian motion 
(rotation and tumbling) causes scattering of emitted light. Scattering results in a lower 
degree of polarized signal compared to the polarization of the excitation. Larger 
molecules have a slower rotation rate in solution, light emitted is not as severely distorted 
from the plane of excitation; the polarization is preserved. 
Bid is a BH3-only protein known to bind to the BH3 domain of Mcl-1 with high 
affinity. For our competition assay, the peptide binding domain of Bid was labeled with a 
fluorescein (FAM) fluorophore.  If the small molecule of interest binds to this BH3 
domain of Mcl-1 to displace the FAM-Bid fluorescent substrate, a higher concentration 
of fluorescent peptide would be present in solution. Because unbound FAM-Bid is much 
smaller than the peptide-protein complex, fluorescence emission is scattered as a result of 
the faster tumbling; a low polarization signal ensues (Figure 4.2). Controls used for this 





Figure 4.2 | Schematic of fluorescence polarization assay. Fluorescence anisotropy is 
based on the principle that a static fluorophore emits polarized light when excited by a 
polarized source; the movement of the fluorophore in solution ‘scrambles’ the emitted 
light relative to the angle of incident polarization. When a fluorescently labeled peptide 
that possesses the BH3-only domain of protein Bid (FAM-Bid) binds to Mcl-1, the size 
of the complex slows fluorophore tumbling. The emitted light from the complex remains 
on the same plane as the excitation light; the polarization signal is preserved. Small 
molecules tumble faster in solution, which more severely distorts the polarization plane 
of radiated light. If a compound binds to Mcl-1 as to displace or avert FAM-Bid binding, 
a higher concentration of FAM-Bid will persist in solution. The faster tumbling of the 
unbound fluorescent protein scrambles radiated light, resulting in a lower fluorescence 





Seven small molecules out of the 96 screened demonstrated weak affinity in the 
protein-based assay; none of the molecules exhibited any effect near the potency recorded 
for 60 (0.32 µM) (Figure 4.4). The purpose of the biochemical evaluation, however, was 
to narrow down the top scoring molecules from the virtual screen to determine a scaffold 
for upcoming rational elaboration.   
 
 
Figure 4.3 | Controls for fluorescence polarization assay. (a) (-)-Epigallocatechin 
gallate (EGCG), a compound commonly found in green and black tea, has been shown to 
have potent binding affinity to the BH3 domain of members of the Bcl-2 family. This 
small molecule was used as a control for our competition assay. (b) Titration of Bid 
protein showed to out compete constant concentrations of the fluorescent FAM-Bid 







Figure 4.4 | Structures of ‘hit’ small molecules from initial FP assay. 96 compounds were 
selected to represent 1,054 commercially available compounds that demonstrated a Glide score of 
-8.5 or better for Mcl-1. The 96 compounds were tested in a fluorescence polarization assay to 
experimentally assess affinity for the protein target. The structures of the compounds 
biochemically tested accompany the results of the FP assay, and the Glide scores from 
computational evaluation. The lower % FAM bound shows binding affinity for the molecule to 
the target as a result of FAM-Bid BH3 protein displacement. 
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4.2.4. Selection of molecular scaffolds 
To better select molecular scaffolds to use as a basis for further optimization, we 
returned to the ~600,000 small molecule in silico library, and filtered it for compounds 
that show >75% structural similarity to at least one of the experimentally validated ‘hits.’ 
1,479 compounds resulted, which were each docked into the Mcl-1 crystal structure. 
Again, the top scoring compounds (-9.0 or greater) were ordered and experimentally 
analyzed by fluorescence polarization. 
Again, compounds tested demonstrated very weak affinity for the purified Mcl-1 
protein (>100 µM). Chemical structures and binding orientations were compared across 
the compounds that exhibited the greatest affinity for Mcl-1 in our fluorescence 
polarization assay, and trends were observed. The indolene scaffold was observed in 
K11, M12, and K05, and assumed similar occupation of the protein pocket upon docking.  
We then built in silico libraries of commercially available indoles and indolenes 
to establish a scaffold amenable to synthetic modification. The structures of M12, K05, 
and similar compounds include substitution of the indole at the nitrogen; base-catalyzed 
alkylation and acylation at this position can be accomplished through deprotonation of 
the nitrogen atom to make the anion the most nucleophilic site on the ring. Guided by this 
hypothesized synthetic accessibility, we designed in silico libraries of commercially 
available alkyl and acyl halides, which we computationally reacted with the indole to 
create a new library that was docked into the crystal structure of Mcl-1. Elaboration at the 
indole nitrogen led to an increase in binding scores. We continued this iterative process 
of identifying locations on the molecule amenable to synthetic elaboration, designing 
libraries of commercially accessible reactants used to create more complex, yet 
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synthetically accessible compounds, and re-docking the newly established libraries into 




Figure 4.5 | Workflow to computationally design synthetically accessible small 
molecules. The structures of molecules that demonstrated the best binding affinity in the 
fluorescence polarization assay were analyzed for similarity. Guided by the docking pose 
of the molecules in the receptor binding pocket, synthetically accessible reactive sites 
were chosen. Using this strategy, we observed an increase in docking score, correlating 






Figure 4.6 | Small molecule fit inside Mcl-1 binding pocket. The small molecule 
designed to fit inside the receptor was optimized to have strong interactions with the 
basic sidechain of the arginine amino acid residue in position 263. The molecule shown 
has a docking score of -12.25; interactions contributing to this increased affinity include 
the hydrogen donating capabilities of the hydroxyl-substituent on the phenyl ring with 
Ala 227, the pi-stacking interactions with that ring and Phe 270, and the Leu 267 
interactions with the hydroxyl substituent on the 6-position of the indole. 
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4.2.5 Computational assessment of small molecule specificity for Mcl-1 
 Part of our criteria was to design a small molecule that demonstrated specificity 
for Mcl-1 over other members of the Bcl-2 family of proteins. We hypothesize this 
binding selectivity would reduce off-target effects. The ‘hit’ compounds (Glide scores 
 
Scheme 4.1 | Proposed synthesis of designed small molecules. Starting with the 
commercially available tri-substituted aromatic compound, the methoxy substituent could 
be selectively deprotected with BBr3 in the presence of the ester. The resulting hydroxyl 
group could undergo subsequent alkylation with methylallyl bromide. Next, 
saponification of the ether moiety to an acid, followed by thionyl chloride addition could 
reveal a reactive acyl chloride, to which an indole could be conjugated at the N-position 
under basic conditions. Subsequent Suzuki coupling using the aromatic boronic acid to 
react with the aromatic bromide, followed by oxidative cleavage of the terminal olefin 
results in synthesis of the final small molecule for biochemical analysis. 
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ranging from -11 to -13 for Mcl-1) were docked into one crystal structure of Bcl-2 and 
two crystal structures of Bcl-XL.  Our molecules did not demonstrate comparable affinity 
to either Bcl-2 or Bcl-XL as for Mcl-1; Bcl-2 Glide scores (PDB structure 4AQ3) ranged 
from -4.21 to -5.88, and Bcl-XL docking scores (PDB structures 2O1Y and 3ZK6) range 
from -4.6 to -7.7. Although the docking scores predict our molecules have greater affinity 
for Mcl-1 over Bcl-2 and Bcl-XL, these scores do not correlate to a specific KD value. 
Consequently, when comparing the docking scores for one small molecule across all 
protein targets, we cannot assume differential affinity observed is sufficient to confer 
physical selectivity. Although there is no substitute to experimentation, small molecules 
known to bind to Bcl-2 and Bcl-XL (e.g., ABT-263 and ABT-199) could be docked in 
Bcl-2 family protein structures to generate scores for comparison. Computationally 
studying small molecules with experimentally determined affinities can better guide our 
computational assessment of new compound selectivity for Mcl-1 over other Bcl-2 
family proteins. 
 To computationally predict ADME properties (absorption, distribution, 
metabolism, excretion) of the set, QikProp calculations were run. Including ADME 
prediction and optimization early in the drug development process can significantly lower 
late-stage therapeutic attrition rate, as almost 40% of lead candidates fail in clinical trials 
because of poor pharmacokinetic/pharmacodynamic properties (Li, 2001). QikProp 
calculations (Schrodinger) can quickly predict over twenty pharmaceutically relevant, 
physical descriptors, including aqueous solubility, octanol/water or water/gas partition 
coefficients, predicted blood/brain barrier coefficient, Caco-2 cell permeability, or 
predicted IC50 for blockage of HERG K+ channels. When applied to our top-scoring, 
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synthetically accessible molecules, good drug-like characteristics were predicted for all 




Figure 4.7 | Calculated ADME properties of designed Mcl-1 inhibitors. Shown here 
are a few parameters of those calculated, including predicted octanol/water partition 
coefficient (QPlogPo/w, range of recommended values: -2.0 - 6.5), predicted apparent 
Caco-2 cell permeability to model the gut-blood barrier (QPPCaco, range of 
recommended values: < 25 = poor, > 500 = great), rule of five (number of violations of 
Lipinski’s rule of five: molecular weight < 500, hydrogen bond donor </= 5, hydrogen 
bond acceptor </= 10, and Log value of the octanol/water partition coefficient < 5), and 
percent human oral absorption (< 25% is poor,  > 80% is high). 
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4.3 Discussion  
 We set to examine computer-aided drug design methods as an alternative to 
NMR-based screening of fragment libraries for Mcl-1 target specificity. Informing in 
silico drug development methods with biochemical assays provides an attractive 
approach to synchronize the efficiency of computational methods with the experimental 
molecule activity. We observed challenges in small molecule solubility when working 
with ligands in the fluorescence polarization assay, which were valuable physical 
phenomena that can greatly influence further rational lead compound design. Virtual 
docking strategies are much less laborious than the physical screening, yet we did not 
elucidate any fragments with potent binding in vitro. This is not surprising, as the Mcl-1-
BH3-only protein-protein interaction area is very large, and is extremely difficult to 
abrogate solely through low MW (< 300 KDa) small molecule binding.  
 The generation of additional, distinct docking grids, centered over diverse sites on 
the BH3 domain of Mcl-1, could allow us to cover a larger surface area with the 
fragments. Fragments that demonstrate good docking scores for different regions of the 
BH3 binding groove can then be synthetically tethered together to create a large molecule 
with increased affinity. 
We were able to design synthetically accessible small molecules that 
demonstrated a favorable docking pose inside the BH3 domain of Mcl-1, which may act 
as efficacious BH3-mimetics. The scoring functions were extremely promising (< -12).  
Although empirical scoring functions do not correlate to any measure of small molecule 
activity (e.g., a dissociation constant, KD), it does give a good illustration of the 
conformation the ligand assumes inside the binding pocket, and informs us that there are 
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very favorable physical parameters for binding to occur. The eventual synthesis of the 
designed small molecules, followed by testing for Mcl-1 specific activity (e.g., activity in 
Mcl-1 dependent cell lines, activity dependent on Bax/Bak oligmerization, specificity for 
Mcl-1 over Bcl-2/Bcl-XL) would shed light on the actual efficacy of our CADD 
methodology towards Mcl-1 inhibition. 
 
4.4. Methods  
 
Docking Software   
Molecular docking was performed using GLIDE (version 2012, Schrodinger, Inc). 
Modeling of proteins and ligands were performed using Molecular Operating 
Environment [MOE] (Chemical Computing Group). All chemical structures were drawn 
using ChemDraw Ultra version 10.0. (Perkin Elmer). All statistical analyses, EC50 
determinations, and viability curves were produced using Prism 5.0c (GraphPad 
Software).  
In silico libraries 
Libraries of commercially available compounds were compiled from the inventories of 
Asinex, Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge and TimTec.  A subset 
of ~600,000 compounds was obtained from the unfiltered library using the following 
filter criteria: LogP <3, hydrogen bond acceptors ≤ 3, hydrogen bond donors ≤ 3, 
molecular weight <300, aqueous solubility > 0.5 mM. Chemical descriptors were 
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calculated using MOE (Chemical Computing Group). Designed libraries of synthetically 
accessible compounds were compiled using selected commercially available reagents 
from the inventory of Sigma-Aldrich and Chem-Impex using the Combigen application 
in MOE (Chemical Computing Group).  
His-tagged Mcl-1 ΔC ΔN protein purification 
Transformed Escherichia coli BL21 (DE3) were cultured in kanamycin-containing Luria 
Broth, and protein expression was induced by the addition of 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) once the optical density reached 0.8. The bacterial pellets 
were resuspended in buffer (50 mM Tris, 50 mM NaCl, 1 mM DTT, pH 8.0, complete 
protease inhibitor tablet) for sonication. After centrifugation at 45,000 xg (15,000 rpm) 
for 45 minutes, the supernatant was applied to a column of Ni Sepharose Fast Flow beads 
(GE Healthcare, Catalog 17-5318-01) for affinity purification. A 20 mM imidazole wash 
(x 3) was completed before applying 250 mM imidazole solution to the column for 
protein elution. Gel electrophoresis confirmed His-tagged Mcl-1 presence; additional 
purification by FPLC was accomplished if necessary to enhance purity. 
Fluorescence polarization binding assay 
Direct binding curves were obtained through the incubation of FAM-labeled BID protein 
(30 nM) with serial dilutions of purified His-tagged Mcl-1 protein in FPA buffer (50 mM 
NaCl, 50 mM Tris, pH 7.4, 1mM DTT), and fluorescence polarization measured at 30 
min on the Victor 3 plate reader (PerkinElmer). For competition assays, a serial dilution 
of small molecule or acetylated peptide was added to 1 µM MCL-1. Fluorescence 
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polarization was measured at equilibrium by nonlinear regression analysis of competitive 



















Conclusions and future directions 
 
5.1 Summary and conclusions 
 
Experimental approaches to the discovery of small molecule probes and drug 
candidates often use biochemical or cell-based screening of large libraries (>105) of small 
molecules. Small molecules of interest are tested one at a time in individual wells of a 
microtiter plate, at a significant cost in time and resources. Furthermore, evaluation of 
large numbers of compounds in such assays requires robust cellular or biochemical 
screening formats that may not be relevant to the contexts found in human patients.  
The purpose of this dissertation is to examine these challenges encountered in 
currently implemented methods of small molecule drug discovery, and to propose a 
microparticle-based screening system that can allow for screening of small molecules in 
such a pooled fashion, analogous to the pooled, cell-based screens of genetic reagents 
that have been powerfully deployed in recent years.  
First, we define an appropriate solid phase vehicle upon which to develop this 
small molecule delivery system for pooled screening. Fluorescent, carboxylate-coated 
silica microparticles provided enough sites for chemical diversification while sufficiently 
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being internalized by human cell lines. The beads maintained their structure and 
fluorescence throughout organic chemical reaction conditions. Their fluorescent property 
allows for convenient particle tracking throughout the assay and for clear distinction from 
cellular debris produced upon assay completion. 
Next, we developed a cleavable linker that can link small molecules of interest to 
silica microparticle beads. Chemical diversification was possible through common 
bioconjugation reactions (EDC couplings, maleimide chemistry). Because the bead enters 
the cell through endocytosis, it is exposed to an environment rich in proteases instead of 
cytosolic thio-reductases; a cathepsin D cleavable linker provided more efficient release 
of the small molecule from the bead, as evidenced by observed cellular lethality, than a 
disulfide linker. 
We introduced a bead-based fluorescent sensor that can report on the activity of 
small molecules in cells. A FRET-based, gain-of-function sensor of apoptotic activity 
effectively distinguished the beads exposed to active caspase 3 from an uncleaved, 
population. This reporter was designed to provide initial insight into the ‘hit small 
molecule’s mechanism of action, allowing this pooled screening method a clear 
improvement over traditional phenotypic screens. 
The final component to this screening system is a DNA tag encoding the identity 
of the small molecule, attached to each silica bead through a photocleavable linker to 
enable its amplification. This barcode is unique to each small molecule subject to the 
assay, yet is designed to possess identical priming regions, conserved throughout each 
barcode to allow for equal amplification probability. The system is amenable to 
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sequencing using NGS techniques, so that a statistical distribution of barcodes results 
from the screen. 
We suggest that a pooled small molecule screening system could ultimately have 
a significant impact on drug discovery, by allowing rapid and inexpensive screening of 
small molecules in more complex assays potentially of greater relevance to human 
diseases.    
Finally, we investigated in silico strategies to design a small molecule inhibitor of 
the anti-apoptotic protein, MCL-1. This target-based, computational approach can be 
used to efficiently build molecular complexity in a directed fashion, keeping the structure 
of the binding site in mind while elaborating on the molecule’s structure to optimize 
affinity for the designated pocket. Molecular scaffolds were established through iterative 
docking and biophysical assessment of fragments. The computational course by which to 
elaborate on the small molecule’s structure was motivated by the experimental results; 
more complex, yet synthetically accessible compounds were proposed. Each 
demonstrates strong computational binding scores for Mcl-1 inhibition. 
 
5.2 Future directions 
Targeting specific organelles to guide a therapeutic to its specific intracellular 
active site has become an objective in drug discovery, with the goal to reduce side effects 
such as systemic toxicity, and to lower the effective dosage required for activity. 
Endosomal/ lysosomal targeting is one application of this technology, as there are 
numerous diseases associated with the disruption of lysosomal function. Lysosomal 
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storage disorders include Tay-Sachs disease, Gaucher’s disease, Fabry disease, Hurler 
syndrome, Pompe disease, etc.; however, lysosomes have also been implicated in 
Alzheimer’s disease and autoimmune diseases. Often, low enzymatic activity in the 
endosome or lysosome contributes to these disorders. The reduced digestion of 
internalized components acts to diminish cellular function through downstream protein 
deactivation. 
As the system stands, this technology enables the cell-based screening for small 
molecules that mechanistically enhance enzymatic activity in endosomes or lysosomes. 
The design of this technology would include the small molecule linked to the bead 
through a cathepsin-cleavable or pH sensitive linker, so that the small molecule is 
released only when exposed to the acidic environment of the organelle to be targeted. We 
have demonstrated the efficacy of the cathepsin cleavable linker to join lethal molecule 
MMAE to the bead. Similarly, a reporter of lysosomal enzymatic activity would include a 
FRET pair with a specific substrate sensitive to cleavage by enzymes known to have 
diminished or eradicated activity as result of the diseased state, replacing our current 
caspase-sensitive peptide sequence.  
A reporter sensitive to cleavage by lysosomal glycoside hydrolase 
glucocerebrosidase (GCase) activity could be designed, to screen for small molecules that 
specifically increase its enzymatic activity. Mutations in the GBA1 gene, which encodes 
for GCase, are a key pathological feature of the lysosomal storage disorder Gaucher’s 
disease, and have been identified as a genetic risk factor for Parkinson’s disease. 
Depletion of GCase results in abnormal accumulation of glucosyl ceramide inside 
lysosomes; current therapeutic strategies rely on enzyme replacement therapy to increase 
 122 
GCase presence inside the lysosome. Fluorogenic substrates of GCase activity in live 
cells have been described for imaging in fibroblasts (Yadav et al., 2015) and can be 
adapted to develop a reporter specific to GCase for application to our technology. 
This principle can also be applied to Tay-Sachs disease. This disease is 
characterized by mutations of the gene HEXA, which encodes for the lysosomal enzyme 
β-hexosaminidase A. Significantly decreased amounts of β-hexosaminidase A prevents 
degradation of the GM2 ganglioside lipid in neurons, leading to its accumulation which 
results in neurodegeneration (Myerowitz, 1997). Provided a specific peptide substrate for 
β-hexosaminidase A is included between FRET pairs of our reporter, libraries of small 
molecule candidates can be screened in a pooled-method to cherry-pick molecules that 
enhance the enzymatic activity of β-hexosaminidase A.  
Endosomal escape of the internalized bead would expand the scope of this 
technology. Methods to increase the internalization of histidine-labeled microparticles by 
including cell-penetrating peptides may enable both efficient cell uptake and cytosolic 
access to the established technology. Endosomal escape of the three- component Bead-
Barcode-Reporter-Small molecule system may also be encouraged by the co-treatment of 
the system with photosensitizers that specifically embed in the lysosomal membrane. 
Upon exposure to light, the ROS production from these organic molecules destructs the 
organelle’s membrane to allow access of the system to the cytosol. 
Once the bead has access to the cytosolic environment, screening for apoptosis-
inducing small molecules is possible through the disulfide-cleavable, small molecule 
linker in conjunction with the cleaved caspase 3-sensitive, FRET-based activity reporter. 
The reporter acts to provide a first-pass insight into the hit small molecule’s mechanism 
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of action, greatly aid in narrowing down the possibilities of the molecule’s direct protein 
target to enhance the probability of discovering a successful therapy. Moreover, the 
reporter can shed light on unexpected mechanisms of action of small molecules, 
contributing to a more complete picture of how the molecule perturbs a biological 
system.   
In addition to caspase detection, the reporter can be tuned to provide mechanistic 
information on the activation of diverse enzymes in response to small molecule 
intervention. Autophagy, for example, is a catabolic, protective cellular process 
associated with the lysosomal degradation of unnecessary or harmful biological products. 
The dysregulation of autophagy can contribute to neurodegeneration, cancer, or 
infectious diseases; as such, up-regulating autophagy, and thereby encouraging the 
removal of toxic and aggregate proteins or harmful microbes, has become an attractive 
therapeutic strategy (Rubinsztein et al., 2015). By designing the linker that bridges the 
FRET pair to include peptide substrates specific for Atg4 cysteine proteases, the pooled 
screen can be used to discover small molecules that promote autophagy. Atg4 is present 
in the cytosol; the cleavage of Atg8 by Atg4 is essential for autophagosome biogenesis 
and eventual autophagy (Shu et al., 2010). Simply tweaking the reporter component to 
respond to protease activity indicative of a distinct physiological process enables efficient 
identification of small molecules as therapeutic candidates or biological probes through a 
pooled, cell-based screen. 
Eventual synthesis of the small molecules designed to bind to the BH3 groove on 
Mcl-1 would be completed and tested for Bax/Bak dependent apoptosis to examine 
MOA.  
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This work establishes a strategy upon which to create libraries of compounds for 
pooled small molecule screening, which is a powerful means to combine targeted drug 
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Table A1: Peptide sequences used for reporter component 







  CEY_NH2_HIS NH2(PEG3)-HHHHHHHHHHHHHHH 
Bead-FITC CEY NH2FITC NH2(PEG3)(FITC)KGDEVD 
  CEY-DEVD2 
NH2-(miniPEG3)-Gly-Asp-Glu-Val-Asp-Gly-
Gly-Lys-(FITC) 
  CEY-DEVD NH2(mini-PEG3)-DEVD-FITC 
 
Table A2: Barcode sequences and primers 
  Sequence Name Sequence 
Bead-
oligo 
CEY_PCNH_rc_TruSeqBC1 /5AmMC12//iSpPC/CCT TGG 
CAC CCG AGA ATT CCA 
ACG GCA TAC GAG ATC 
GTG ATG TGA CTG GAG TTC 
AGA CGT GTG CGA TCG 





CEY_PCNH_TruSeqBC2 /5AmMC12//iSpPC/GTT CAG 
AGT TCT ACA GTC CGA CTG 
AAC TCC AGT CAC CGA TGT 
ATC TCG TAT GCC GTC TTC 
TGC ACA TTG TGG AAT TCT 
CGG GTG CCA AGG 
control CEY_TruSeq_BC2_PAGE GTT CAG AGT TCT ACA GTC 
CGA CTG AAC TCC AGT 
CAC CGA TGT ATC TCG TAT 
GCC GTC TTC TGC ACA TTG 
TGG AAT TCT CGG GTG CCA 
AGG 
control CEY_TruSeqBC1 GTT CAG AGT TCT ACA GTC 
CGA CGA TCG CAC ACG 
TCT GAA CTC CAG TCA CAT 
CAC GAT CTC GTA TGC CGT 
TGG AAT TCT CGG GTG CCA 
AGG 
control CEY_TruSeqBC1_revcomp CCT TGG CAC CCG AGA ATT 
CCA ACG GCA TAC GAG 
ATC GTG ATG TGA CTG 
GAG TTC AGA CGT GTG 
CGA TCG TCG GAC TGT 
 142 
AGA ACT CTG AAC 
control CEY_NH_TruSeqBC1 /5AmMC12/GTT CAG AGT 
TCT ACA GTC CGA CGA TCG 
CAC ACG TCT GAA CTC 
CAG TCA CAT CAC GAT CTC 
GTA TGC CGT TGG AAT TCT 
CGG GTG CCA AGG 
Primer 1 CEY_TruSeq_RPI1 CAA GCA GAA GAC GGC 
ATA CGA GAT CGT GAT 
GTG ACT GGA GTT CCT TGG 
CAC CCG AGA ATT CCA 
Primer 2 CEY_TruSeq_RP1 AAT GAT ACG GCG ACC 
ACC GAG ATC TAC ACG TTC 
AGA GTT CTA CAG TCC GA 
 
